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 Defective vasculature is one of the hallmarks of many diseases ranging from restricted 
blood flow in ischemia to abnormal blood vessel growth in cancer. Intravenous administration is 
particularly beneficial to patients with vascular-related diseases which are not easily accessible 
by the conventional methods. Therapeutics delivered via this route, however, must overcome the 
barriers along the way from the entry into the bloodstream to the target destination. To maximize 
the therapeutic efficacy, this dissertation investigates the use of polymeric nanoparticles to 
improve the transport of intravenously administered therapeutics and their accumulation in the 
diseased sites.  
  The first part of this dissertation focuses on the delivery of mesenchymal stem cells to 
ischemic tissue. Chapter 2 presents the use of nanoparticles capable of enhancing the ability of 
stem cells to migrate across defective vascular walls. The surface of stem cells was tethered with 
particles that sustainably released stromal cell-derived factor-1α.  Intravenously injected stem 
cells consequently exhibited a higher migration ability to ischemic muscle. The strategy of 
surface tethering was then applied towards protecting stem cells in the oxidative diseased sites, 
as presented in Chapter 3. The nanoparticles are devised to rapidly discharge antioxidant 
epigallocatechin gallate in response to elevated levels of hydrogen peroxide. The stem cells 
survived in sub-lethal concentrations of hydrogen peroxide and maintained their angiogenic 
potential in vivo.  
 The second part of this dissertation looks at the delivery of doxorubicin to cancer cells. 
Chapter 4 presents the design strategies of nanoparticles for an enhanced release of entrapped 
doxorubicin within cancer cells. By incorporating moieties sensitive to the intracellular signals of 
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cancer cells, drug release from the particles was significantly accelerated, giving rise to superior 
in vivo antitumor efficacy. Ultimately, the results of this dissertation will greatly contribute to 
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CHAPTER 1: INTRODUCTION 
 
1.1 Vascular-Related Diseases and Conventional Treatments 
 Blood, the river of life, flows through the arteries and veins in our circulatory system 
where nutrients are carried to the cells and waste products being removed from the body1. 
Disorders in this vast network of blood vessels causing either a shortage of blood flow or 
excessive blood supply can result in a range of health problems which can be fatal.  
 
1.1.1 Ischemic Diseases 
Ischemia is a vascular pathological condition where blood supply is restricted due to the 
blockage of vascular wall by fatty deposits (i.e. atherosclerosis) or by thrombus and embolus2,3. 
A prevalent manifestation of ischemia in the lower extremities, peripheral artery disease (PAD) 
has affected more than 202 million people worldwide4. Prolonged deprivation of oxygen and 
nutrients due to inadequate blood flow could lead to necrosis of the surrounding tissues5. 
Cytokines are consequently upregulated in these injured sites for the recruitment of immune cells 
and other cell types to restore tissue homeostasis6. 
A traditional treatment of PAD, peripheral artery bypass is a surgery that reroutes the 
blood supply around the blocked artery with a graft which is commonly a vein taken from the 
patient7. Given the invasiveness of this surgery, bypass is not suitable for many due to ages and 
health complications7. Moreover, there is a 20% risk of amputation 5 years following the bypass 
surgery8. While balloon angioplasty and stenting are a less invasive way to open clogged arteries 
than the bypass surgery, the procedure involves the risks of restenosis due to overgrowth of scar 
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tissue which may obstruct the blood flow again7. Thus, there are grand needs to improve the 
quality and outcome of treatment for PAD patients via other minimally invasive ways.  
 
1.1.2 Cancer 
Cancer, the second leading cause of global deaths, is characterized by rapid proliferation 
of cells and invasion into surrounding healthy tissue9,10. To support the fast-growing cancer cells, 
blood vessels in the solid tumor microenvironment are excessively developed, giving rise to 
structurally leaky endothelium9,10. Compared to the normal tissue where adjacent endothelial 
cells lining the blood vessels are tightly connected, gaps between tumor endothelial cells can 
vary by hundreds of nanometers11,12. In addition, the lymphatic vessels in the tumor site are 
usually malfunctional, resulting in local accumulation of fluid9,10. Owning to the leakiness of 
endothelium and the poor drainage system, tumors often exhibit the enhanced permeability and 
retention (EPR) effect10.  
 Chemotherapy is a key cancer treatment and is often used in conjunction with other 
treatments including radiotherapy to increase the success rate of eradicating cancer cells13,14. 
Most anticancer drugs target cells which are dividing15, and rapid division is a hallmark 
characteristic of cancer cells. Unfortunately, these drugs lack the ability to distinguish cancer 
cells from the normal dividing ones such as hair follicle cells, leading to hair loss as one of the 
undesirable side effects16. A more adverse effect is cardiotoxicity which may occur during 
therapy or manifests years after treatment17,18. Depending on the types of chemo drugs and the 
cumulative dosages, the incidence of chemotherapy-induced cardiotoxicity ranges from < 1% to 
more than 50%19. One plausible mechanism is the production of free oxygen radicals from these 
drugs which could lead to necrosis of cardiomyocytes18. In some instances, a patient may outlive 
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his or her cancer but die due to heart failure. Such adverse effects of chemotherapy have 
prompted efforts to circumvent the problem of non-selective toxicity of cancer drugs.  
 
1.2 Intravenous Delivery of Therapeutics  
Amongst the various routes of administration of therapeutics, intravenous injection is one 
of the fastest ways of delivering medications through circulation20,21. More importantly, this 
route is highly favored for its minimal invasiveness as well as the ability to deliver therapeutics 
to sites which are less accessible by the conventional methods. Furthermore, drug dosing through 
intravenous injection can be easily adjusted and conveniently repeated if necessary to achieve the 
desired concentration of drug in the blood21. 
 
1.2.1 Mesenchymal Stem Cells  
Mesenchymal stem cells (MSCs) are a population of non-hematopoietic fibroblastoid-
like-cells residing mainly in the bone marrow and in adipose tissues22,23. Given their capability to 
secrete a diverse repertoire of immunomodulatory cytokines and therapeutic growth factors, 
MSCs are widely being recognized as the regenerative medicine for treating a series of acute and 
chronic ischemic diseases24-26.   
At the injured sites, cross-talks between immune cells and the transplanted MSCs activate 
the secretion activity27. For example, interferon-gamma and tumor necrosis factor alpha released 
by lymphocytes and macrophages stimulate the immunomodulatory action of MSCs to suppress 
inflammatory response28,29. Additionally, transforming growth factor alpha produced by 
macrophages activates the signaling pathways in MSCs to secrete vascular endothelial growth 
factor for revascularization, the basis of treating ischemic diseases30. Improved blood flow 
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recovery was demonstrated in the acute ischemic hindlimb of mice transplanted with MSCs31,32.  
Moreover, a phase 2 clinical trial involving 77 patients with critical limb ischemia showed better 
recovery with a delay in the onset of adverse events such as pain in the extremities after 
receiving one-time injections of stem cells33. More importantly, no safety issues such as tumor 
formation were observed with the clinical use of MSCs for treating ischemic limb diseases33,34. 
 
1.2.2 Small Molecule Cancer Drugs  
A rapidly increasing variety of chemotherapeutic drugs has been developed over the past 
decades. Of which, the anthracyclines are the most effective class ever developed and are 
effective against more types of cancer than any other classes35,36. As small molecule drugs, 
anthracyclines are easily absorbed by cells which then intercalate the DNA to inhibit cellular 
division37. Having gained approval from the Food and Drug Administration since year 1974, 
Adriamycin® (doxorubicin) remains a widely used option in chemotherapy despite a ~20% 
incidence of inducing cardiotoxicity18,36. The non-specific toxicity of doxorubicin can be 
alleviated by encapsulating the drug into nanocarriers and delivering them intravenously. An 
extensive list of studies has demonstrated a significant reduction of drug toxicity in other organs 
when nanoparticles are employed37-39. Furthermore, the EPR effect contributes to the 
accumulation of these nanoparticles in the extravascular space of tumors40.  
 
1.3 Biological Barriers to Intravenous Delivery  
 From the entry into the blood circulation to the intended destination, therapeutics are 
bound to encounter barriers along the way which could minimize their accumulation at the 
diseased sites. This, in turn, limits the therapeutic efficacy. 
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Therapeutics in circulation must undergo a cascade of multi-step migration process 
involving the vascular endothelium before exiting the bloodstream into the injured tissue. 
Despite sufficient evidence to show this migration process in MSCs41,42, it appears inefficacious 
because only a small proportion of intravenously transplanted stem cells managed to reach the 
target sites (i.e. < 10%)42-44. While the exact migration mechanism of MSC to injured sites is 
unelucidated, accumulative studies revealed similar comparisons with that of leukocytes to 
injured tissues and hematopoietic stem cells to bone marrow45 (Figure 1.1). Circulating cells 
would first roll and tether along the endothelium as they decelerate and come to a stop45. These 
cells then undergo firm adhesion with the underlying endothelium via multiple ligand/integrin 
interactions such as very late antigen 4 and vascular cell adhesion molecule (VLA4/VCAM-1)45. 
Finally, the cells migrate through the endothelium into the interstitial space, a process known as 
transendothelial migration or extravasation45. Of these three distinct stages, transendothelial 
migration of MSCs has captured much research attention as these cells inherently lack the 
capability to do so. Existing efforts and the proposed approach to overcome the endothelial 
barrier are elaborated in Chapter 2.  
 MSCs which have successfully extravasated and arrived at the injured sites are now 
exposed to a harsh environment where reactive oxygen species (ROS) are overproduced46. Poor 
survival of these transplanted MSCs due to excessive ROS is identified as the second barrier to 
the success of stem cell therapy. During normal cellular metabolism, ROS in the form of 
superoxide anion (O2
•−), hydrogen peroxide (H2O2) and hydroxyl radical (
•OH) are produced 
from molecular oxygen46. These oxygen centered molecules containing unpaired valence-shell 
electrons are unstable and reactive with the biological molecules inside the cells47. At low doses 
of ROS, cells can defend themselves against oxidative damage using specific ROS reducing 
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mechanisms that can be enzymatic or non-enzymatic. Enzymatically, superoxide dismutase 
catalyzes the dismutation of superoxide anion radical into H2O2, which in turn is converted to 
water and oxygen by glutathione peroxidase (GPx) and catalase47. Non-enzymatic compounds 
such as ascorbic acid, α-Tocopherol and β-Carotene prevent the formation of molecules with 
unpaired valence-shell electrons by donating electrons to them47.  
On the other hand, high doses or inadequate removal of ROS could result in excessive 
buildup of oxidative stress in the cells. This could lead to apoptosis when the free radicals 
irreversibly inactivate the intracellular biological molecules47. Consequently, the transplanted 
stem cells may die before they could secrete the therapeutic cytokines and growth factors at the 
injured sites. Existing efforts and the proposed approach to protect these transplanted MSCs from 
H2O2-induced damage are detailed in Chapter 3.  
The employment of nanoparticles in the delivery of small molecule cancer drugs is 
intended to reduce the non-specific drug toxicity by containing these drug molecules and 
transporting them to the tumor site. In contrast to MSCs which deliver their therapeutic effects 
within the extravascular tissue spaces, the majority of small molecule cancer drugs works 
intracellularly49. Depending on several factors including the geometry and surface charge of the 
nanoparticles, the extent of endocytosis in cancer cells varies48. For those which are successfully 
internalized from the cell membrane, they will be transported in the early endosomes and be 
delivered to the late endosomes followed by the lysosomes49. Hydrolytic enzymes in the late 
endosomes and lysosomes would degrade the cargos within the vesicles49. Since anthracyclines 
are DNA intercalating agent, they must be released from the nanoparticles before enzymatic 
degradation takes place. Lethargic intracellular release of drugs, however, limits the amount of 
therapeutics available to eradicate the cells and presents as a barrier to the delivery of anticancer 
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drug50. Designing stimuli-responsive nanoparticles is a strategy to promote drug release, with the 
details elaborated in Chapter 4.  
 
1.4 Research Overview  
This dissertation seeks to improve the therapeutic outcome of intravenously administered 
MSCs and drug-loaded nanoparticles for the treatment of acute ischemia and cancer, 
respectively. To do so, the biological barriers to the delivery of these therapeutics ought to be 
overcome, namely 1) limited capability of MSCs to migrate across the vascular endothelium into 
the underlying injured tissue, 2) poor survival of the transplanted MSCs in an oxidative 
environment of the injured tissue, and 3) lethargic release of encapsulated anticancer drugs from 
nanoparticles within the cancer cells.  
Chapter 2 introduces an approach to improve the transport of MSCs to the ischemic 
hindlimb of a murine model. By tethering the cellular surface with polymeric nanoparticles 
containing stromal cell-derived factor-1α, the expression of CXC chemokine 4, a receptor 
actively involved in the migration of cells, was upregulated. This approach of surface tethering 
with nanoparticles is adopted in Chapter 3 which aims to improve the survival of MSCs in a 
H2O2-rich environment. At elevated levels of H2O2, antioxidant epigallocatechin gallate was 
rapidly released from the nanoparticles with the help of MnO2 nanosheets. Chapter 4 investigates 
the release rate of doxorubicin from stimuli-responsive polymeric nanoparticles and the extent of 
reducing non-selective drug toxicity in a mouse xenograft model of breast cancer. Finally, 
Chapter 5 concludes the dissertation and provides some directions. Overall, the results of this 
work will serve to increase the therapeutic efficacy of a wide array of therapeutic stem cells and 






Figure 1.1. Three distinct stages of migration of mesenchymal stem cells into the extravascular 
spaces of injured tissue45. Stage 1: Circulating stem cells undergo rolling and tethering along the 
endothelium as they decelerate in the blood flow. Stage 2: The stem cells express surface 
receptors such as very late antigen 4 (VLA-4) which bind specifically to vascular cell adhesion 
molecule (VCAM-1) overproduced on the injured endothelium. This ligand-integrin interaction 
helps strengthen the adhesion of stem cells to the endothelium as they become firmly arrested. 
Stage 3: The arrested stem cells undergo transendothelial migration as they cross over the 
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CHAPTER 2: IMPROVING TRANSENDOTHELIAL MIGRATION OF 
INTRAVENOUSLY INJECTED MESENCHYMAL STEM CELLS AND 
ACCUMULATION IN THE MURINE ISCHEMIC HINDLIMB 
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2.2 Introduction  
Intravenous administration of mesenchymal stem cells (MSCs) is performed to treat 
various vascular diseases1,2. The ability of these stem cells to adhere to the defective endothelium 
of the injured tissue and undergo transendothelial migration is critical to the success of stem cell 
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therapy. Unfortunately, MSCs expanded through in vitro culture have poor ability to undergo the 
transendothelial migration, which likely leads to the low engraftment level at target sites (i.e., < 
10 %)3-5.  
This challenge prompted efforts to understand and harness the molecular mechanisms 
involved in homing of hematopoietic stem cells (HSCs) to bone marrow as well as that of 
leukocytes to injured sites. Stromal cell-derived factor-1α (SDF1α) and CXC chemokine receptor 
4 (CXCR4) are the key ligand/receptor complexes to facilitate the homing of HSCs and 
leukocytes6,7. SDF1α is actively produced by stromal cells in the bone marrow, or by endothelial 
cells and fibroblasts in extracellular matrix of injured tissues7-10. Regardless of the production 
route, these chemokines are localized on the luminal surface of endothelium where they interact 
with surface receptor CXCR4 of circulating HSCs and leukocytes6,7,11. Subsequent binding of 
SDF1α with CXCR4 leads to polarization of cellular actin filaments and activates the 
mechanotransduction responsible for migrating across the endothelial barrier7,11.  
In comparison to HSCs and leukocytes, a smaller fraction of MSCs (i.e. < 4%) expresses 
CXCR4 on their surface12,13. Some studies also reported a drastic decline in the CXCR4 
expression following isolation and in vitro expansion of MSCs12,14. Consequently, these cells 
displayed limited migration toward a SDF1α gradient in vitro12.  
To increase the surface expression of CXCR4, efforts were made to transduce MSCs with 
viral gene encoding CXCR412,15,16. The viral transduction has shown to be effective in 
upregulating these surface receptors. However, the use of viral vectors may hinder clinical 
application due to safety concerns and risks of tumorigenic potential17,18. Therefore, a non-
genetic approach such as exposure of MSCs to recombinant SDF1α before transplantation has 
been employed to stimulate the expression of surface CXCR4. MSCs are typically incubated in 
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culture media supplemented with recombinant SDF1α for 0.5-2 hours, and they have 
demonstrated a greater in vitro transendothelial migratory ability than non-conditioned cells19-22. 
Additionally, SDF1α-preconditioned fetal MSCs were intraperitoneally injected into a mouse 
model of osteogenesis imperfecta, and they exhibited higher engraftment in the bone and bone 
marrow20. Unfortunately, xenogeneic products are often present in media (i.e., animal-derived 
serum in the culture media) and may elicit immune responses.  
To this end, this study demonstrates a facile strategy that stimulates MSCs to express 
CXCR4 in circulation and subsequently increases the number of MSCs migrating to target 
injured tissues. We hypothesized that particles anchoring to the cell surface and releasing SDF1α 
sustainably would activate the CXCR4 expression of MSCs, and in turn promote their 
transendothelial migration into the ischemic tissue (Figure 2.1). We examined this hypothesis by 
encapsulating recombinant SDF1α into nanoparticles prepared using block copolymers of 
poly(D,L-lactide-co-glycolide) (PLGA) and hyaluronic acid (HA), denoted as PLGA-b-HA. HA 
blocks of the particles served to bind specifically to CD44 receptors on MSCs. 
This study evaluated the effects of length of HA blocks in PLGA-b-HA on the binding 
affinity of nanoparticles to the MSC surface. We assessed the average mass of the nanoparticles 
tethered onto MSCs and their distribution on the cell surface. The fraction of MSCs that 
expressed CXCR4 surface receptors was determined by flow cytometry. Transendothelial 
migration of MSCs was studied by quantifying the number of MSCs that crossed over 
endothelium in a Transwell® system and a microfluidic chip. Finally, we examined the 
trafficking efficacy of MSCs by injecting the cells into circulation of mice with an acute 





2.3.1 Synthesis and Characterization of PLGA-b-HA Nanoparticles 
End-to-end coupling between carboxylate group of poly(D,L-lactide-co-glycolide) 
(PLGA) and amino group of amine-functionalized hyaluronic acid (HA) led to the formation of 
PLGA-b-HA (Figure 2.2)23. The amphiphilicity of the PLGA-b-HA was demonstrated by 
dissolving the block copolymers in deuterated water or organic solvent, dimethyl sulfoxide 
(DMSO) and examining 1H NMR spectra (Figure 2.3). The characteristic peaks of the PLGA 
block were observed at 5.21, 4.91 and 1.47 ppm in deuterated DMSO (Figure 2.3A-1 and 2.3B-
1). In deuterated water, however, these peaks became broader. Also, the peaks of HA block at 
3.36 – 4.60 ppm were more pronounced in the deuterated water than in the deuterated DMSO 
(Figure 2.3A-2 and 2.3B-2). 
 Double emulsification of the PLGA-b-HA copolymer resulted in uniformly sized 
spherical nanoparticles as observed under the transmission electron microscope (Figure 2.4A). 
Increasing the molecular weight of HA from 5 to 10 kDa slightly increased the average 
hydrodynamic diameter of the PLGA-b-HA particles from 182 ± 5 to 216 ± 8 nm, as measured 
with the dynamic light scattering unit (Figure 2.4B, Table 2.1). HA blocks in the PLGA-b-HA 
copolymer served to decrease the zeta potential of nanoparticles from -24 mV to -35 mV when 
dispersed in deionized water (Figure 2.4C). In contrast, PLGA and PLGA-b-HA particles 
suspended in phosphate buffered saline (PBS) showed a smaller difference in the zeta potential. 
 
2.3.2 Binding Kinetics of PLGA-b-HA Nanoparticles to MSCs 
 We tethered rhodamine-labeled nanoparticles onto cells by mixing MSCs together with 
the particles for 15 min in suspension. Successful adhesion of these particles onto MSCs was 
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identified by the co-localization of red fluorescence from particles and green fluorescence from 
cell surface. Cells incubated with PLGA-b-HA particles presented a 1.9-fold higher red 
fluorescence signal than those incubated with PLGA particles (Figures 2.5A-i to 2.5A-vi and 
Figure 2.5B). Furthermore, increasing the molecular weight of HA in PLGA-b-HA from 5 to 10 
kDa led to a 1.4-fold increase in the fluorescence emission yield. 
 Interestingly, PLGA-b-HA nanoparticles tethered to the surface of MSCs were self-
organized in a form of clusters with an average diameter of 1 µm (Figures 2.5A-iii to 2.5A-vi). 
Likely because of the cluster formation, MSCs took up a minimal number of PLGA-b-HA 
nanoparticles at 24 h after mixing (Figures 2.5A-ix to 2.5A-xii). Following 24 h, the fluorescence 
emission yield for PLGA nanoparticles decreased by 1.5-fold while that of PLGA-b-HA (10kDa) 
remained similar to that at 0 h (Figure 2.5B).  
 We further quantified the average mass of particles on surface of MSCs per cell using a 
standard curve of fluorescence intensity against concentration of particles. The average mass of 
PLGA-b-HA (10kDa) nanoparticles per cell was approximately 6-fold higher than that of PLGA 
nanoparticles (Figure 2.5C). The molecular weight of HA also contributed to increasing the 
number of particles bound to cells by 1.6 times. 
 Additionally, we evaluated the binding affinity of nanoparticles to MSCs by measuring 
the association rates (k1) and dissociation rates (k-1) of particles with cells (Figure 2.6A). 
Assuming a bimolecular reversible reaction between a nanoparticle and a surface receptor on the 
stem cell, k1 values of particles to MSCs was determined by quantifying the number of 
rhodamine-labeled particles binding to the cell surface with Eq. (1) and Eq. (2).   
 
                                    (1)  
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Where NC is the number of particles binding to cellular surface per cell, NRT is the total number 
of surface receptors per cell, CL0 is the total concentration of particles in the media,  is the 
dissociation equilibrium constant. 
                                                
With known and measured values of CL0, Nc, and NRT, CL0/Nc in Eq. (1) was linearly related 
to CL0. NRT and KD could be calculated from the slope and intersection of the linear fitting curve, 
respectively.  
  values of particles from cells was assessed by quantifying the number of particles 
separated from the cells over a period of 20 min using Eq. (3). Detachment of cells was 
performed under an orbital speed equivalent to blood linear velocity of aorta.   
 
 
Where the NC is the number of particles bound to cells, NC0 is the number of particles initially 
bound to cells, and t is the incubation time point.  
 With measured values of NC and NC0, ln (NC/NC0) was linearly related to t. k-1 values 
could be subsequently quantified from the slope of the linear fitting curve. Finally, k1 was 
obtained from using Eq. (1) and Eq. (2). 
Accordingly, the association rate of PLGA-b-HA (10kDa) nanoparticles was 3.3-fold 
higher than that of the PLGA particles (Figure 2.6B). Increasing the molecular weight of HA 
from 5 to 10 kDa in the PLGA-b-HA led to a 2.9-fold increase in the association rate. In 
addition, PLGA nanoparticles dissociated from the cells faster than PLGA-b-HA (5kDa) and 
PLGA-b-HA (10kDa) particles by 4-fold and 5-fold, respectively (Figure 2.6C).  




 The binding affinity (KA) of PLGA-b-HA (10kDa) nanoparticles to cells, a ratio of the 
association rate to the dissociation rate, was 20-fold higher than that of PLGA particles (Figure 
2.6D). Increasing molecular weight of HA in PLGA-b-HA from 5 to 10 kDa increased the value 
of KA by 4.5-fold (Figure 2.6D). Using the calculated values of KA we further assessed the 
binding free energy (Wbinding) of particles to surface of MSCs using Eq. (4)
24. 
           (4) 
Where kB is Boltzmann constant and T is the working temperature at 25 °C. The Wbinding of 
PLGA-b-HA (10kDa) particles is -8.78 × 10-20 J, which is 1.1-fold and 1.2-fold higher than that 
of PLGA-b-HA (5kDa) and PLGA particles, respectively (Figure 2.6E).  
 Given that PLGA-b-HA (10kDa) nanoparticles yielded a higher binding affinity to MSCs 
than PLGA-b-HA (5kDa), PLGA-b-HA (10kDa) nanoparticles were chosen as the representative 
particles for all following studies related to cell delivery. 
 
2.3.3 In situ Stimulation of CXCR4 in MSCs with SDF1α-releasing PLGA-b-HA 
Nanoparticles  
Recombinant SDF1α was encapsulated into PLGA and PLGA-b-HA (10kDa) 
nanoparticles by emulsifying polymers in the oil phase with SDF1α dissolved in an aqueous 
phase followed by second emulsification in another aqueous media. The encapsulation efficiency 
of SDF1α in PLGA and PLGA-b-HA (10kDa) particles were 84% and 88%, respectively (Figure 
2.7A). In a simulated physiological environment of pH 7.4, both PLGA and PLGA-b-HA 
(10kDa) particles released SDF1α continuously over 3 days in a similar manner (Figure 2.7B). 
We analyzed the ability of SDF1α-loaded nanoparticles to stimulate CXCR4 expression 
of MSCs following 24 h of treatment. According to the images of cells immunostained with an 
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antibody to CXCR4, MSCs tethered with SDF1α-loaded PLGA-b-HA (10kDa) nanoparticles 
(Figures 2.8A-xi to 2.8A-xiii) displayed a 5-fold higher CXCR4 expression per cell than 
untreated MSCs (Figures 2.8A-i, 2.8A-ii, and 2.8A-xiii). On the other hand, MSCs tethered with 
SDF1α-loaded PLGA nanoparticles (Figures 2.8A-vii, 2.8A-viii, and 2.8A-xiii) and those 
exposed to SDF1α solution (Figures 2.8A-iii, 2.8A-iv, and 2.8A-xiii) at an equivalent 
concentration exhibited an average of 2.5-fold increment in CXCR4 expression per cell as 
compared to untreated MSCs. Particles without SDF1α induced negligible changes in the level of 
CXCR4 expression, regardless of the chemical composition of nanoparticles (Figures 2.8A-v to 
2.8A-x, and 2.8A-xiii). 
In parallel, we counted the number of MSCs with positive expression of extracellular 
CXCR4 using flow cytometry. SDF1α-loaded PLGA-b-HA (10kDa) nanoparticles demonstrated 
the highest number of extracellular CXCR4-positive cells with a 7-fold increase as compared to 
untreated MSCs (Figures 2.8B-i, 2.8B-vi, and 2.8B-vii). SDF1α solution and SDF1α-loaded 
PLGA nanoparticles, in contrast, only doubled the number of extracellular CXCR4-positive 
MSCs (Figures. 2.8B-ii, 2.8B-v and 2.8B-vii). Blank nanoparticles did not have any observable 
stimulatory effects to the expression of extracellular CXCR4 (Figures 2.8B-iii, 2.8B-iv, and 
2.8B-vii). 
 
2.3.4 In vitro Transendothelial Migration of MSCs 
We next examined the transendothelial migration of MSCs using the Transwell® assay. 
Fluorescently labeled stem cells were added to the top compartment of Transwell® pre-seeded 
with endothelial cells (Figure 2.9A). Endothelial cells were treated with tumor necrosis factor 
(TNF-α) to simulate an inflamed environment25. Additionally, recombinant SDF1α was added to 
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the bottom compartment of the Transwell® to attract MSCs from the top compartment. After 16 
h, the percentage of transmigrated MSCs was quantified by measuring the fluorescence intensity 
from cells in the bottom compartment. MSCs tethered with SDF1α-encapsulating PLGA-b-HA 
(10kDa) nanoparticles displayed a 1.3-fold higher transendothelial migration than those tethered 
with blank nanoparticles (Figure 2.9B). SDF1α-loaded PLGA particles did not significantly 
increase the number of MSCs that undertook extravasation. 
We further evaluated transendothelial migration of MSCs in a microfluidic chip with 
endothelium grown along the vertical interface of the fibrin gel (Figure 2.9C). Fluorescently 
labeled MSCs were seeded in the same channel where the endothelial cells were pre-seeded and 
exposed to TNF-α. Following 4 h, untreated MSCs were mostly arrested on the endothelium 
along the vertical interface (Figures 2.9D-i and 2.9E). On the contrary, MSCs tethered with 
SDF1α-encapsulating PLGA-b-HA (10kDa) nanoparticles demonstrated an increased 
transendothelial migration by 1.2 times as compared to untreated MSCs (Figures 2.9D-ii and 
2.9E). 
 
2.3.5 Analysis of the Transport of MSCs in a Mouse Ischemic Hindlimb Model 
The efficacy of nanoparticles to improve transport of MSCS to an injured tissue was 
examined by systemic injection of the cells into mice with an ischemic hindlimb. The ischemia 
was induced by ligation of the femoral artery in the left hindlimb (Figure 2.10A). MSCs were 
labeled with a near-infrared (NIR) fluorescence dye, CellVue® NIR815. The fluorescence 
intensity of the dye was proportional to the number of MSCs (Figure 2.10A-i). Cells were 
tracked with the In vivo Imaging System (IVIS) following 24 h of cell injection. 
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MSCs tethered with SDF1α-encapsulating PLGA-b-HA (10kDa) nanoparticles produced 
a 1.7-fold higher fluorescence yield in the ischemic hindlimb than that of the untreated MSCs 
(Figure 2.10B). This corresponded to approximately 3.6 × 103 of MSCs per square centimeter of 
the hindlimb tissue and was 1.7-fold higher than that of untreated cells (Figure 2.10C). Blank 
PLGA-b-HA (10kDa) nanoparticles did not increase the number of MSCs that migrated to the 
ischemic hindlimb.   
Importantly, this improved targeting efficiency was specific for mice with ischemic 
hindlimb. When injected with MSCs tethered with SDF1α-loaded PLGA-b-HA (10kDa) 
particles, the non-ischemic hindlimb displayed a two-fold smaller number of MSCs than the 
ischemic hindlimb (Figures 2.10B and 2.10C). This result was attributed to the 1.3-fold lower 
endogenous SDF1α level in the non-ischemic hindlimb than the ischemic hindlimb (Figure 
2.10D). In contrast, the number of untreated MSCs accumulated in the heart, liver, spleen, and 
kidneys of mice with an ischemic hindlimb was comparable to those of MSCs tethered with 
SDF1α-loaded PLGA-b-HA (10kDa) particles, respectively (Figure 2.11A and 2.11B). Mice 




This study demonstrates that nanoparticles capable of releasing SDF1α on MSC surface 
stimulated migration of MSCs into ischemic tissue following intravenous injection. For this 
purpose, we employed PLGA-b-HA (10kDa) particles as a carrier of recombinant SDF1α. Since 
MSCs express CD44 surface receptors which bind specifically to HA26, a larger number of 
PLGA-b-HA (10kDa) nanoparticles adhered to the surface of MSCs than PLGA particles. This 
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increased number was attributed to an elevated binding affinity due to the HA-CD44 interactions 
between PLGA-b-HA particles and MSCs which are not available to the PLGA particles. 
 We further extrapolated the binding energy caused by HA-CD44 interactions (WHA-CD44) 
from the total binding free energy (Wbinding) of PLGA-b-HA particles to MSCs, as calculated 
using Eq. (4). Assuming that the Wbinding was driven primarily by energies from colloidal 
interactions (i.e. Van der Waals attraction (Wvdw) and electrostatic repulsion (Welectrostatic) and 
specific interactions (i.e. binding of HA to CD44), we calculated WHA-CD44 using Eq. (5).  
                                       (5) 
 Given the significant difference in the size between the nanoparticles (~200 nm) and cells 
(~20 µm), the surface of cells is considered flat for an approaching particle. Therefore, Wvdw 
between the particles of radius R and MSCs at a distance D was assessed with Eq. (6)27. 
                                     (6)   
Where A is the effective Hamaker constant for interaction between PLGA-based particles and 
cells in PBS (approximated as 0.5 x 10-20 J)28. We assumed that Wvdw is the same for both PLGA 
and PLGA-b-HA nanoparticles.  
 The electrostatic repulsion energy, Welectrostatic, between the particles of radius R and 
MSCs at a distance D is approximated using Eq. (7)29.  
                    (7)                                 
Where Z = (9.22 x 10-11)tanh2(ψo/103) at 25 °C (J m
-1)29, ψo is the zeta potential of the particles 
(Figure 2.4C), and b is the Debye length in PBS (~0.8 nm).    
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 Assuming that the Wbinding of PLGA nanoparticles to MSCs was modulated only by both 
Van der Waals and electrostatic repulsion interactions, the value of D in Eq. (6) and Eq. (7) was 
presumed to be the distance where the value of Wbinding and the summed value of Wvdw and 
Welectrostatic are matched. The Wbinding of PLGA particles was determined to be -7.54 × 10
-20 J 
(Figure 2.6E). At D of 1.1 nm, the summed value of Wvdw (-7.58 × 10
-20 J) and Welectrostatic (8.79 × 
10-22 J) of PLGA particles is comparable with their Wbinding at -7.51 × 10
-20 J. At the same 
distance D of 1.1 nm, the Welectrostatic of PLGA-b-HA (10kDa) particles is approximately twice 
that of PLGA particles at 1.75 × 10-21 J.  Overall, as per Eq. (5), the binding energy value due to 
HA-CD44 interactions at D of 1.1 nm are -7.15 × 10-21 J and -1.38 × 10-20 J for PLGA-b-HA 
(5kDa) and PLGA-b-HA (10kDa) particles, respectively. 
Taken together, the calculation of WHA-CD44 discloses that the molecular weight of HA 
plays a notable role in increasing the binding free energy and affinity of PLGA-b-HA particles to 
MSCs. Specifically, given that the association rate of PLGA-b-HA (10kDa) is higher than that of 
PLGA-b-HA (5kDa) particles, we propose that a higher molecular weight of HA tends to have a 
stronger bond with CD4426. The small difference of the dissociation rate between PLGA-b-HA 
(5kDa) and PLGA-b-HA (10kDa) implies negligible entropic difference towards the detachment 
of particles from the cells. 
In addition, the level of CXCR4 expression in MSCs tethered with SDF1α-loaded PLGA-
b-HA nanoparticles was more prominent than those incubated in media containing an equivalent 
concentration of SDF1α over the same duration of exposure. Since the molecular weight of 
SDF1α is small (i.e. 8 kDa)30, we speculate that SDF1α in the solution was under constant 
Brownian motion. It is highly likely that the continuous motion of SDF1α hindered the 
settlement of these molecules to the surface of MSCs. In contrast, SDF1α molecules released 
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from PLGA-b-HA nanoparticles were in close proximity to the cellular surface. This proximal 
delivery of SDF1α facilitated the activation of extracellular CXCR4 expression.   
We further propose that the improved migration efficiency of MSCs to the ischemic 
hindlimb of mice was likely the combination of the increased number of CXCR4 expressing 
MSCs and an upregulated endogenous SDF1α expression in the ischemic site. Specifically, we 
envision that the recombinant SDF1α released from PLGA-b-HA (10kDa) nanoparticles would 
stimulate circulating MSCs to express extracellular CXCR4 in situ. Subsequent binding between 
CXCR4 of MSCs and endogenous SDF1α on the injured endothelium in the ischemic hindlimb 
would stimulate MSCs to exert force on the underlying endothelium. The stem cells then breach 
the barrier and transmigrate into the perivascular muscle31,32. In addition to the overexpressed 
endogenous SDF1α, we speculate that a repertoire of inflammatory cytokines such as interferon 
gamma and insulin-like growth factor-1 were overproduced in the ischemic tissue. These factors 
likely contributed to the higher fold-increment of cellular migration to the ischemic tissue than 
that in the in vitro transendothelial migration assays33. Accumulation of systemically 
administered cells in non-target organs is inevitable. However, no safety issues such as tumor 
formation were observed with the clinical use of MSCs for treating ischemic limb diseases34. 
To the best of our knowledge, this is the first report on effective modulation of cellular 
transport using proximal delivery of recombinant SDF1α on the MSC surface. Previous efforts 
utilized genetic modifications of MSCs to up-regulate CXCR4 for enhanced cellular migration to 
ischemic tissues12. Others include pretreatment of MSCs in SDF1α-supplemented media before 
transplantation. In contrast, our procedure of tethering PLGA-b-HA (10kDa) nanoparticles to 
MSCs could be readily conducted in a clinical setting. First, the short mixing process of particles 
and cells for 15 min does not necessitate the exposure of stem cells to media containing animal-
27 
 
derived nutrients (e.g. fetal or horse serum), thus reduces potential xenogeneic immune 
responses. Second, MSCs collected from the adipose tissues of a patient in an operating room 
can be injected into circulation following the simple, on-site tethering process. 
 
2.5 Conclusions 
In conclusion, this study demonstrated a clinically facile non-genetic approach to regulate 
the transport of intravenously transplanted stem cells. PLGA-b-HA nanoparticles encapsulating 
recombinant SDF1α were bound to MSCs through HA-CD44 interactions. Increasing the 
molecular weight of HA in these particles elevated the average number of particles on cells and 
in turn, the mass of SDF1α to stimulate cellular expression of CXCR4. Accordingly, SDF1α-
releasing PLGA-b-HA nanoparticles raised the expression level of CXCR4 in individual cells 
and the number of MSCs positive for CXCR4. These MSCs displayed an enhanced 
transendothelial migration along a gradient of SDF1α in vitro and an improved migration to the 
ischemic muscle following intravenous administration in vivo. We envisage that the results of 
this study would significantly contribute to enhancing the therapeutic efficiency of transplanted 
stem cells in treating a wide array of acute and chronic vascular-related diseases. 
 
2.6 Materials and Methods  
2.6.1 Materials  
All chemicals were obtained from Sigma-Aldrich (U.S.A.), and used as received unless 
specified. Hyaluronic acid (HA) of molecular weights 5kDa and 10kDa were purchased from 
Lifecore Biomedical (U.S.A.). PLGA with an acid end group and molecular weights ranging 
from 6,000 to 10,000 g/mol (lactic acid: glycolic acid = 50:50) was purchased from LACTEL 
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Absorbable Polymers, DURECT (U.S.A). Recombinant murine SDF1α and mouse TNF-α were 
purchased from Pepro Tech Inc. (U.S.A.) and VWR Funding Inc. (U.S.A.), respectively. Mouse 
SDF1α ELISA kit was obtained from Fisher Scientific Company (U.S.A). Anti-CXCR4 antibody 
(rabbit monoclonal to CXCR4) was bought from Abcam Incorporated (U.S.A.) while mouse 
anti-rabbit CFL 647 secondary antibody were from Santa Cruz Biotechnology (U.S.A.). Anti-
VCAM-1 antibody (mouse monoclonal to VCAM-1) and goat anti-mouse Alex Fluro 647 
secondary antibody were purchased from Invitrogen (U.S.A.). Transwell® inserts (PET, 
diameter of 6.5 mm, pore size of 8.0 µm) were purchased from Corning® (U.S.A.). Rhodamine 
B conjugated bovine serum albumin (BSA-Rhodamine B) was prepared by reacting 1 mg/mL of 
Rhodamine B isothiocyanate (dissolved in DMSO) with 6 mg/mL of BSA (dissolved in 0.1 M 
sodium bicarbonate buffer, pH 9.2). BSA-Rhodamine B was purified via dialysis against water 
and lyophilized prior to usage. All experiments involving BSA-Rhodamine B were performed in 
the dark.  
 
2.6.2 Cell Culture 
Bone marrow-derived mouse mesenchymal stem cells (D1 ORL UVA), and C166 mouse 
endothelial cells were purchased from ATCC (U.S.A.). Cells were cultured using DMEM 
medium containing 4.5 g/L glucose and L-Glutamine with sodium pyruvate (Lonza, U.S.A.) 
supplemented with 10% fetal bovine serum (FBS, Life Technologies, U.S.A.), 100 U/ml 
penicillin (Lonza, U.S.A.) and 100 µg/ml streptomycin (Lonza, U.S.A.) under 37 °C, 5% CO2. 





2.6.3 Synthesis of Block Copolymer of PLGA and HA (PLGA-b-HA) 
PLGA-b-HA was synthesized using an end to end coupling strategy23 as follows: 
a) Synthesis of N-Hydroxysuccinimide-Functionalized PLGA (PLGA-NHS)  
PLGA with an acid end group (PLGA-COOH) (1 g, 1.2 × 10-4 mol) was charged to a 
reaction vial containing 6 mL of dichloromethane dissolved with NHS (72 mg, 6.3 × 10-4 mol) 
and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (120 mg, 6.3 × 10-4 mol). 
The reaction proceeded for 24 h at room temperature under stirring. The crude product was then 
precipitated twice into cold ethyl ether, centrifuged, washed in cold mixture of ethyl ether and 
methanol (1:1 v/v), and vacuum dried to yield a white crystalline solid. 
b) Synthesis of Aminated HA  
 HA was functionalized with an amine group using the terminal reductive amination 
reaction. 200 mg of HA with an average molecular weight (MWavg) of 10kDa was dissolved in an 
acetate buffer (6 mL, pH 5.6, 2% w/w). 83 µL of 1,4-diaminobutane was added dropwise into the 
HA solution under stirring at room temperature. The reaction continued at 50 °C for 24 h. 
Following 24 h, reducing agent sodium cyanoborohydride (15.3 mg, 0.24 mol) was added to the 
reaction vial each day for consecutive three days. The crude product was purified via dialysis 
(Spectra/Por® Dialysis Tubing, MWCO: 1 kDa) against de-ionized (DI) water for 48 h. The 
resultant product was lyophilized to yield a pale yellowish solid. Aminated HA with MWavg of 5 
kDa was synthesized using the same protocol. 
c) Synthesis of PLGA-b-HA  
 PLGA-NHS (120 mg, 1.5 × 10-5 mol) dissolved in 8 mL dimethyl sulfoxide and aminated 
HA with MWavg of 10 kDa (150 mg, 1 × 10
-5 mol) were transferred into the reaction vial. N, N-
Diisopropylethylamine (4.4 µL, 2.5 × 10-5 mol) was subsequently added dropwise, and the entire 
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mixture was reacted for 48 h at 50 °C under stirring. The resultant block copolymer was then 
purified by dialysis (FisherbrandTM Regenerated Cellulose Dialysis Tubing, MWCO: 12 kDa-14 
kDa) against DI water for 48 h, harvested and lyophilized to give a white solid. PLGA-b-HA 
(5kDa) was also synthesized using the same protocol, but with the amount of reagents scaled 
accordingly. 
 
2.6.4 Preparation and Characterization of Nanoparticles Encapsulating BSA labeled with 
Rhodamine B (BSA-Rhodamine B) or Recombinant SDF1α 
Nanoparticles loaded with BSA-Rhodamine B or recombinant SDF1α were prepared 
using the double emulsification method. Briefly, 10 mg of PLGA or PLGA-b-HA was dissolved 
in 0.25 mL of dimethylformamide under sonication, and subsequently charged with 0.75 mL of 
dichloromethane. Then, the mixture was sonicated for 1 h. 100 µL of BSA-Rhodamine B in PBS 
(5 mg/mL) or SDF1α in PBS (1 µg/mL) was added to the organic phase of PLGA or PLGA-b-
HA, and immediately sonicated in an ice-bath for 30 sec using a probe-based sonicator (Fisher 
Scientific Sonic Dismembrator Model 100, U.S.A.) followed by vortexing for 30 sec. The second 
emulsion was produced by introducing the first emulsion into the aqueous solution of polyvinyl 
alcohol (1% v/v PVA). The mixture was sonicated in ice-bath followed by vortexing. The 
resulting nanoparticles were then stirred for ~ 4 h at room temperature for evaporation of organic 
solvents. The particles were collected via centrifugation, washed in DI water, and used for 
further studies or lyophilized for 2 days. 
The resulting particles were imaged with the Transmission Electron Microscopy (JEOL 
2100 Cryo TEM, U.S.A.) using an acceleration voltage of 200 keV. A drop of the particle 
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suspension (5.0 µL) was placed onto a carbon film 200 mesh copper grid. Staining agent, 1% 
w/v phosphotungstic acid (5.0 µL) was placed on the grid and left to dry at room temperature.   
The hydrodynamic diameter and zeta potential of freshly prepared nanoparticles (~1 
mg/mL) was measured at 25 ⁰C using Zetasizer Nano ZS (Malvern (ZEN 3600), UK). Particle 
size was determined using the dynamic light scattering method where the scattered light was 
collected at 173°. The hydrodynamic diameter and zeta potential nanoparticles (~1 mg/mL) was 
measured at 25 oC using the Zetasizer Nano ZS (Malvern ZEN 3600, UK). The particle diameter 
was determined using the dynamic light scattering unit where the scattered light was collected at 
173°. The zeta potential of the nanoparticles in DI water and PBS was calculated from the 
Smoluchowski model as follows35:  
 
Where  is the zeta potential, is the electrophoretic mobility of medium,  is the dielectric 
constant of the medium, and  is approximated as 1.5. 
 
2.6.5 Analysis of Binding of Nanoparticles to MSCs 
a) Tethering of MSCs with Nanoparticles 
 3.3 mg of PLGA and PLGA-b-HA nanoparticles were mixed with 1 × 105 D1 cells at 
room temperature and allowed to stand for 15 min. Unbound particles in the supernatant were 
removed via centrifugation and the cell pellet was resuspended with media for subsequent 
studies.  
b) Analysis of the Spatial Distribution of Nanoparticles on MSCs 
MSCs tethered with PLGA and PLGA-b-HA nanoparticles containing BSA-Rhodamine 
B were seeded on glass coverslips and imaged either immediately or 24 h later. The plasma 
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membrane and nuclei of cells were stained with DiO (25 ng/mL, Invitrogen, U.S.A.) and 
Hoechst 33342 (5 µg/mL, Thermo Fisher Scientific, U.S.A.), respectively. The cells were 
washed with PBS and observed with a confocal laser scanning microscope (Carl Zeiss LSM 700, 
Germany). The excitation wavelength (ex) and emission wavelength (em) of each probe were as 
follows: Hoechst 33342 (ex: 350 nm, em: 470 nm), DiO (ex: 480 nm, em: 520 nm), 
Rhodamine B (ex: 532 nm, em: 625 nm). ImageJ software was used to quantitatively determine 
the mean gray value of Rhodamine B per plasma membrane (at least 10 individual cells per 
condition). Values were normalized with respect to the mean gray value of untreated MSCs. 
c) Measurement of the Average Mass of Nanoparticles per MSC 
Unbound particles in the supernatant from a) was measured at an excitation wavelength 
of 535 nm with emission wavelength of 590 nm (Tecan Infinite M200 PRO, Switzerland). A 
standard plot of fluorescence intensity against concentration of particles was obtained to 
determine the concentration of unbound particles in the supernatant. Concentration of particles 
remaining bound to cells was taken as the difference between the initial concentration of 
particles and concentration of unbound particles in supernatant. The mass of particles per MSC 
was calculated by multiplying the volume of cell suspension (i.e. 1 mL) and dividing by 1 × 105 
cells. Average mass of particles per MSC was evaluated from three individual samples per 
condition.  
d) Measurement of the Association Rate Constants (k1) 
1 × 105 MSCs were incubated with nanoparticles encapsulated with BSA-Rhodamine B 
(5 mg/mL) for 15 min. The particle concentration (CL0) was varied from 0.05 to 3.3 mg/mL. 
Unbound particles in the supernatant were collected via centrifugation. The fluorescence 
intensity at wavelength of 590 nm was measured using a microplate reader A plot of CL0 against 
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CL0/Nc was obtained, with KD/NRT as the slope, where KD = k-1/k1, and NRT is the total number of 
receptors per cell (Eq. (1)).  
e) Measurement of the Dissociation Rate Constants (k-1) 
The cell suspension from c) was then placed under orbital shaking at 150 rpm (Barnstead 
International multi-purpose rotator, U.S.A.) for 1, 2, 5, 10, and 20 min at 37 °C, 5% CO2. At the 
designated time points, the cell suspension was centrifuged and the supernatant containing 
unbound particles was collected. The fluorescence intensity of supernatant was measured at an 
excitation wavelength of 535 nm with emission wavelength of 590 nm (Tecan Infinite M200 
PRO, Switzerland). A standard curve of fluorescence intensity against concentration of particles 
was obtained. Concentration of particles remaining on cells (Nc) was determined as the 
difference between the initial concentration of particles on cells (NC0) and concentration of 
unbound particles in supernatant. Three replicates were tested for each condition. A graph of 
Ln(Nc/NC0) against time was then plotted, with k-1 as the slope (Eq. (3)).  
f) Binding Affinity ( ) 
 The binding affinity of nanoparticles to cells was evaluated using the following equation:  
 
 
2.6.6 Analysis of the Encapsulation Efficiency and Release of SDF1α 
Encapsulation efficiency and release of SDF1α by PLGA and PLGA-b-HA nanoparticles 
was quantified by using the SDF1α ELISA kit where tetramethylbenzidine (TMB) dye was used 
as the labeling substrate. 10 mg/mL of particles loaded with recombinant SDF1α was centrifuged 
at 12,000 rpm for 5 min, and the supernatant containing free SDF1α was collected for ELISA. 
The absorbance of TMB dye, which is proportional to the amount of SDF1α, was measured at 
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450 nm with a reference wavelength of 550 nm using the microplate reader. A standard plot of 
absorbance against concentration of SDF1α was obtained. Mass of the encapsulated SDF1α was 
determined as the difference between initial loading of 0.1 µg and mass of SDF1α in supernatant, 
and encapsulation efficiency of SDF1α was calculated as follows:  
 
To quantitatively assess the release rate of SDF1α, 10 mg of particles loaded with SDF1α was 
subjected to shaking at 100 rpm. The temperature was kept constant at 37 °C.  Periodically, the 
particles were centrifuged at 12,000 rpm for 5 min, and the supernatant was collected to quantify 
the concentration of SDF1α. The particles were then re-suspended with 1 mL of fresh PBS. 
 
2.6.7 Analysis of CXCR4 Expression in MSCs 
MSCs tethered with blank or SDF1α-loaded nanoparticles were seeded on glass 
coverslips in a 12-well plate at a density of 1 × 105 cells per well. Cells were cultured at 37 °C 
under 5% CO2 atmosphere. After 24 h, the cells were fixed with 3.7% formaldehyde and 
permeabilized with 0.1% Triton-X for 10 min at room temperature. The cells were then blocked 
with 1% BSA solution for 1 h at room temperature, which was followed by overnight incubation 
with 5 µg/mL anti-CXCR4 antibodies at 4 °C in a humidified chamber. 2 µg/mL goat anti-rabbit 
IgG-CFL 647 antibody solution was subsequently added to the cells for 45 min at room 
temperature. The actin and nuclei of cells were stained with Alexa Fluor 488® Phalloidin (6.6 
µM, Invitrogen, U.S.A.) and DAPI (0.01 mg/mL, Invitrogen, U.S.A.), respectively for 20 min at 
room temperature. The cells were then washed with PBS, mounted with Vectashield H-1000 
(Vector Laboratories, U.S.A.), and observed under a confocal laser scanning microscope (Carl 
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Zeiss LSM 700, Germany). IgG-CFL 647 was excited at 633 nm to collect fluorescent emission 
at 665 nm. All observations were conducted under the same conditions. ImageJ software was 
then employed to quantitatively determine the mean gray value of IgG-CFL 647 per cell. A 
minimum of 10 individual cells was evaluated per condition. 
 
2.6.8 Analysis of Number of Extracellular CXCR4-Expressing MSCs.  
The fraction of MSCs expressing surface CXCR4 was assessed using flow cytometry 
(BDTM LSR II flow cytometer, U.S.A.). 105 MSCs were preconditioned with 100 ng/mL SDF1α 
for 24 h at 37 °C under 5% CO2 atmosphere. Separately, MSCs were tethered with blank or 
SDF1α-loaded nanoparticles and seeded on a cell culture well for 24 h. The cells were then 
briefly trypsinized (Life Technologies, U.S.A.) and collected with ice-cold PBS containing 10% 
FBS and 1% sodium azide. 10 µg/mL anti-CXCR antibodies was added to the cell suspension 
and incubated at 4 °C for 1 h. The cells were subsequently fixed with 1% formaldehyde at 4 °C 
for 10 min. After washing, cells were re-suspended with 1 mL of ice-cold PBS. 2 µg/mL goat 
anti-rabbit IgG-CFL 647 (Santa Cruz Biotechnology, U.S.A.) was added to the cell suspension, 
and incubated at 4 °C for 45 min. The cells were centrifuged and re-suspended with ice cold PBS 
containing 3% BSA and 1% sodium azide. A minimum of 8 × 10³ cells was assessed with an 
excitation wavelength of 633 nm. Three replicates were tested for each condition. FCS Express 6 
Flow Cytometry Software (De Novo) was used to quantify the percentage of cells with positive 






2.6.9 In vitro Transendothelial Migration of MSCs   
a) Transwell® Assay 
C166 endothelial cells were seeded at a density of 2 × 105 cells on the membrane of 
Transwell® at 37 °C under a 5% CO2 atmosphere overnight, and subsequently treated with 100 
ng/mL TNF-α for 1 h. Separately, MSCs were labeled with Calcein AM (9 µM) and tethered 
with either blank or SDF1α-loaded nanoparticles. The resulting MSCs were then added at a 
density of 6 × 105 to the top compartment of Transwell® with 100 ng/mL SDF1α solution at the 
bottom compartment. A standard curve of fluorescence emission intensity against the number of 
Calcein AM labeled cells was plotted. After 16 h of incubation, the fluorescence emission 
intensity of the bottom compartment was measured at wavelength of 485 nm and converted to 
the number of transmigrated MSCs. Three replicates were tested for each condition. Values were 
normalized with respect to that of MSCs without particles.  
b) Microfluidic Chip Assay 
 Fibrin gel was introduced into the green channel of the microfluidic chip where 
fibrinogen solution (5 mg/mL, F3879 from Sigma-Aldrich, U.S.A.) and thrombin solution (4 
U/mg protein, T7009 from Sigma-Aldrich, U.S.A.) were mixed at a 1:1 volume ratio. Following 
the solidification of fibrin gel in a humidified chamber at 37 °C, C166 endothelial cells were 
seeded at a density of 4 × 105 per chip. The endothelial cells were then treated with 100 ng/mL 
TNF-α for 1 h. MSCs were labeled with CellTrackerTM Orange CMTMR dye (10 µM, Thermo 
Fisher Scientific, U.S.A.) for 30 min and tethered with SDF1α-releasing PLGA-b-HA (10kDa) 
nanoparticles. The cells were then seeded at a density of 5 × 104 per chip. After 4 h of incubation, 
the cells were observed under a confocal laser scanning microscope (Carl Zeiss LSM 700, 
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Germany). The excitation wavelength and emission wavelength of CellTrackerTM Orange 
CMTMR dye were 555 nm and 585 nm, respectively.  
 
2.6.10 Analysis of Biodistribution of MSCs in a Mouse Ischemic Hindlimb Model 
The hindlimb ischemia surgery was performed according to a protocol approved by the 
Institutional Animal Care and Use Committee (IACUC) in the University of Illinois. The animals 
used were CD-1® IGS mice at 7 weeks of age provided by Charles River Laboratories. The mice 
were anesthetized with ketamine (100 mg/kg) via intraperitoneal injection. The hair was 
removed from the left hindlimb of the animal prior to making a small incision at the upper thigh 
to expose the femoral artery and vein. The proximal and distal ends of the femoral artery and 
vein were occluded using double knots with 5-0 Ethilon sutures (Johnson & Johnson, U.S.A.). 
The occluded section was then cut to prevent blood flow into the lower limb. The incision was 
subsequently closed with 5-0 Ethilon sutures.  
 Following 2 h of surgery, the mice were randomly divided into 3 groups (2-4 mice per 
group) for cell injection: Group 1 for untreated MSCs, Group 2 for MSCs tethered with blank 
PLGA-b-HA (10kDa) nanoparticles, and Group 3 for MSCs tethered with SDF1α-loaded PLGA-
b-HA (10kDa) nanoparticles. Mice without the ischemic hindlimb were used as control. MSCs 
were labeled with CellVue® NIR815 (2 µM., LI-COR Biosciences, U.S.A.) and administered at 
a density of 1.5 × 105 per mouse via tail vein injection.  
 The mice were sacrificed 24 h after cell injection, and organs (heart, lungs, liver, spleen, 
kidneys) as well as hindlimbs were harvested for ex vivo imaging (IVIS® SpectrumCT, Perkin 
Elmer, U.S.A.). All images were acquired under the same instrument settings: excitation filter = 
745 nm, emission filter = 840 nm, exposure time = 40 sec, binning factor = 4, f/stop =2, field of 
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view = 14. The living Image® 4.2 software (PerkinElmer, U.S.A.) was used to analyze the 
images. The fluorescence signal was quantified by the free-hand drawing region of interest (ROI) 
over the entire tissue sample and presented as the average radiant efficiency (photos per second 
per square centimeter per steradian divided by microwatts per square centimeter). The resulting 
fluorescence emission intensity of each tissue sample was converted to the number of MSCs 
from a standard curve of the number of cells against their respective fluorescence intensity. 
 
2.6.11 Measurements of SDF1α Level in Ischemic Hindlimb Tissue  
Tissue samples from the dissected hindlimbs were homogenized in ice-cold Tris-HCl 
buffer (100 mM, pH 7.4) containing 150 mM NaCl, 1 mM EGTA, 1 mM EDTA, 1% Triton X-
100, and 0.5 % sodium deoxycholate supplemented with HaltTM protease inhibitor cocktail 
(Thermo Scientific, U.S.A.). The protein extracts were collected via centrifugation, and total 
protein concentration was determined by the Bradford assay (PierceTM Coomassie Plus, Thermo 
Scientific, U.S.A.). Separately, the amount of SDF1α in protein extracts was quantified using the 
ELISA kit for SDF1α. 
 
2.6.12 Statistical Analysis 
All data are expressed as a mean  standard deviation. Statistical analysis between two 
experimental conditions was performed by the Student’s t-test. A value of p < 0.05 indicated a 








2.7 Figures and Table 
 
 
Figure 2.1. Schematic illustration of a strategy for enhanced transendothelial migration of MSCs 
into an ischemic muscle. The surface of CD44-expressing MSCs is tethered with recombinant 
SDF1α-releasing PLGA-b-HA nanoparticles via HA-CD44 interactions. SDF1α released from 
the particles would stimulate MSCs to express CXCR4. Binding of CXCR4 with endogenous 









Figure 2.2. Chemical synthesis scheme of PLGA-b-HA23. (i) Synthesis of amine-functionalized 
HA, (ii) synthesis of N-hydroxysuccinimide-functionalized PLGA (PLGA-NHS), (iii) coupling 











Figure 2.3. 1H NMR Spectra of PLGA-b-HA (5kDa) in (A-1) DMSO-d6 and in (A-2) D2O, and 
PLGA-b-HA (10kDa) in (B-1) DMSO-d6 and in (B-2) D2O. Characteristic peaks of methylene 
(2H, −OCH2-C=O) (a), CH− (b), and methyl (3H, −CH3) (c) in PLGA; methylene (2H, 




Figure 2.4. Characterization of nanoparticles. (A) Transmission electron microscopic images of 
PLGA, PLGA-b-HA where molecular weight of HA is 5 kDa [PLGA-b-HA (5kDa)], and PLGA-
b-HA where molecular weight of HA is 10 kDa [PLGA-b-HA (10kDa)]. Scale bar of the images 
in the first row: 1 µm; scale bar of the images in the second row: 100 nm. (B) Size distribution 
plot of PLGA, PLGA-b-HA (5kDa), and PLGA-b-HA (10kDa) nanoparticles. (C) Zeta potential 
of PLGA, PLGA-b-HA (5kDa), and PLGA-b-HA (10kDa) nanoparticles in deionized water (pH 
7.0) and in phosphate buffered saline (PBS, pH 7.4) The values and error bars represent the 








Figure 2.5. Analysis of nanoparticles being tethered to MSCs. (A) Confocal images of MSCs 
(green) after incubation with nanoparticles (red) for 15 min at room temperature (A-i & A-ii: 
PLGA particles; A-iii & A-iv: PLGA-b-HA (5kDa); A-v & A-vi: PLGA-b-HA (10kDa) 
particles) and 24 h after mixing (A-vii & A-viii: PLGA particles; A-ix & A-x: PLGA-b-HA 
(5kDa); A-xi & A-xii: PLGA-b-HA (10kDa) particles. Nanoparticles were fluorescently labeled 
by loading bovine serum albumin conjugated with Rhodamine B (red). Cell nuclei and plasma 
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Figure 2.5 (cont.) membrane were stained with Hoechst 33342 (blue) and DiO (green), 
respectively. Scale bar: 10 µm. (B) Mean gray value of fluorescence from nanoparticles per cell 
was quantified from at least 10 individual cells using the ImageJ Software at 0 h and 24 h after 
mixing. Values were normalized to that of untreated MSCs. (C) The average mass of particles 
per MSC after incubation for 15 min. The values and error bars in (B) and (C) represent the 
average and standard deviation of three individual samples, respectively. * represents the 
statistical significance of difference in the values between PLGA-b-HA (10kDa) nanoparticles 








Figure 2.6. Analysis of the interaction between nanoparticles and MSCs. (A) A schematic 
illustrating the experimental setup to determine binding kinetics of particles to MSCs. (B) 
Association rate constant (k1), (C) dissociation rate constant (k-1), (D) binding affinity (KA), and 
(E) binding free energy (Wbinding) of nanoparticles. The values and error bars represent the 
average and standard deviation of three samples per condition, respectively. * represents the 





Figure 2.7. Physical characterization of PLGA and PLGA-b-HA (10kDa) nanoparticles. (A) 
Encapsulation efficiency of recombinant SDF1α in the nanoparticles. (B) Time-dependent 
cumulative release of recombinant SDF1α from SDF1α-loaded PLGA and PLGA-b-HA (10kDa) 
nanoparticles. The values and error bars represent the average values and standard deviation of 
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Figure 2.7 (cont.) three replicates per condition, respectively. No statistical significance between 






















Figure 2.8. Analysis of cellular CXCR4 expression. (A) Representative confocal images of 
untreated MSCs (A-i & A-ii), MSCs exposed to recombinant SDF1α solution (A-iii & A-iv), 
MSCs tethered with blank particles (PLGA: A-v & A-vi; PLGA-b-HA (10kDa): A-ix & A-x), 
and SDF1α-loaded nanoparticles (PLGA: A-vii & A-viii; PLGA-b-HA (10kDa): A-xi & A-xii) 
following incubation for 24 h. Cell nuclei were stained with DAPI (blue), and F-actin and 
CXCR4 were labeled with Alexa Fluor® 488 Phalloidin (green) and CFL-647 (red), 
respectively. White lines in (A-i), (A-iii), (A-v), (A-vii), (A-ix), and (A-xi) represent the 
periphery of cells. Scale bar: 10 µm.  Mean gray value of CXCR4 per cell (A-xiii) was evaluated 
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Figure 2.8 (cont.) using the ImageJ Software. The data points and error bars in (A-xiii) represent 
average values and standard deviation of at least 10 individual cells per condition, respectively. 
(B) Representative flow cytometry histograms on the number of MSCs expressing extracellular 
CXCR4 for untreated MSCs (B-i), MSCs exposed to SDF1α solution (B-ii), MSCs tethered with 
blank particles (PLGA: B-iii; PLGA-b-HA (10kDa): B-iv), and SDF1α-loaded nanoparticles 
(PLGA: B-v; PLGA-b-HA (10kDa): B-vi) following incubation for 24 h. A concentration of 100 
ng/mL was used for the recombinant SDF1α in the media and in the particles. Cells were not 
permeabilized and stained with anti-CXCR4 antibodies labeled with CFL-647 fluorescence dye. 
Fluorescence threshold corresponding to cells without CXCR4 antibody staining was set as M1. 
M2 is the percentage (%) of gated cells with positive expression of extracellular CXCR4. The 
values and error bars in (B-vii) represent the average values and standard deviation of three 
replicates per condition, respectively. * represents the statistical significance of difference in the 








Figure 2.9. Analysis of the migration of MSCs through endothelium assembled on a Transwell® 
and in a microfluidic chip. (A) A schematic illustrating the experimental setup for the 
Transwell® assay. Endothelial cells were seeded on the membrane of the Transwell® insert and 
exposed to TNF-α. Calcein AM-labeled MSCs were then added onto the endothelium. The 
recombinant SDF1α was added to the bottom compartment as a chemoattractant. The 
fluorescence intensity of the bottom compartment was measured at 485 nm after 16 h and 
converted to the number of extravasated MSCs. (B) The percentage of transmigrated MSCs was 
represented as the ratio of the number of extravasated MSCs to the initial number of MSCs 
seeded on the Transwell®. The values and error bars represent the average and standard 
deviation of three samples per condition, respectively. (C) A schematic depicting the 
experimental setup for the transendothelial migration study using a microfluidic chip.  
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Figure 2.9 (cont.) Endothelium along the vertical interface between the blue and green channels 
was stained with DAPI and Rhodamine Phalloidin (C-i: side view; C-ii: isometric view). Scale 
bar: 50 µm. MSCs were labeled with CellTrackerTM Orange CMTMR dye (in green pseudo-
color) and added to the blue channel pre-seeded with endothelial cells inflamed by exposure to 
TNF-α. The recombinant SDF1α chemoattractant was added into the pink channel. (D) 
Representative bright-field and fluorescence images of the microfluidic chip were captured from 
top view after 4 h to examine extravasation (orange arrows) of untreated MSCs (D-i) and MSCs 
tethered with SDF1α-loaded PLGA-b-HA (10kDa) nanoparticles (D-ii). Scale bar: 100 µm. (E) 
The total number of transmigrated MSCs in the chip was quantified from the images in (D). The 
values and error bars in (E) represent the average and standard deviation from three chips, 
respectively. * represents the statistical significance of difference in the values between the 






Figure 2.10. Analysis of the transport of intravenously administered MSCs in a mouse with an 
ischemic hindlimb. (A) Illustration depicting the procedure of vascular ligation in the hindlimb 
and systemic injection of MSCs through a tail vein. The MSCs were fluorescently labeled with a 
near-infrared dye, CellVue® NIR815. The dye fluorescence intensity, expressed as average 
radiant efficiency, was proportional to the number of MSCs (A-i). (B) In vivo Imaging System 
(IVIS) images of the hindlimbs captured 24 h after cell injection. Colors of the images represent 
the fluorescence intensity of cells labeled with CellVue® NIR815. 2-4 mice per condition were 
evaluated. All images in (A-i) and (B) were captured with an excitation wavelength of 745 nm 
and an emission wavelength of 840 nm. (C) The number of cells per square centimeter of the 
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Figure 2.10 (cont.) hindlimb tissue. The cell number was quantified based on the fluorescence 
intensity in the IVIS images displayed in (B) using (A-i). (D) The concentration of SDF1α in the 
hindlimbs expressed as pg/mg of protein in the hindlimb tissue. The values and error bars in (C 
& D) represent the average value and standard deviation of two to four different samples per 
condition, respectively. * represents the statistical significance of difference in the values 




Figure 2.11. Localization of fluorescently labeled MSCs in mice by In vivo Imaging System 
(IVIS). (A) Fluorescence intensities of CellVue® NIR815-labeled MSCs in dissected organs of 
mice at 24 h post injection via tail-vein. Representative fluorescence images of the heart, lungs, 
liver, spleen and kidneys of ischemic and non-ischemic mice injected with untreated MSCs, 
MSCs tethered with SDF1α-loaded PLGA-b-HA (10kDa) nanoparticles and blank ones. 2-4 
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Figure 2.11 (cont.) mice per condition were evaluated. All images were taken with an excitation 
wavelength of 745 nm and emission wavelength of 840 nm. (B) Number quantification of MSC 
per square centimeter of tissue in the respective organs based on the IVIS images in (A) using 
the intensity-cell number correlation plot in Figure 2.10A-i. The values and error bars represent 
































Zeta Potential (mV) 
DI water PBS 
PLGA 201 ± 7 0.12 ± 0.01 -24.4 ± 2.1 -2.0 ± 0.3 
PLGA-b-HA 
(5kDa) 
182 ± 5 0.12 ± 0.01 -34.1 ± 1.1 -2.3 ± 0.4 
PLGA-b-HA 
(10kDa) 


















1. Yan, J.; Tie, G.; Xu, T.; Cecchini, K.; Messina, L. M. Mesenchymal Stem Cells as a 
Treatment for Peripheral Arterial Disease: Current Status and Potential Impact of Type II 
Diabetes on Their Therapeutic Efficacy. Stem Cell Rev 2013, 9, 360–372.  
2. Lee, J. S.; Hong, J. M.; Moon, G. J.; Lee, P. H.; Ahn, Y. H.; Bang, O. Y. A long-term 
follow-up study of intravenous autologous mesenchymal stem cell transplantation in 
patients with ischemic stroke. Stem Cells 2010, 28, 1099-1106. 
3. Mooney, D. J.; Vandenburgh, H. Cell Delivery Mechanisms For Tissue Repair. Cell Stem 
Cell 2008, 2, 205-213.  
4. Rombouts, W. J.; Ploemacher, R. E.  Primary Murine MSC Show Highly Efficient 
Homing To The Bone Marrow But Lose Homing Ability Following Culture. Leukemia 
2003, 17, 160-170.  
5. Terrovitis, J. V.; Smith, R. R.; Marbán, E. Assessment and Optimization of Cell 
Engraftment After Transplantation into The Heart. Circ Res 2010, 106, 479-494. 
6. Peled, A.; Kollet, O.; Ponomaryov, T.; Petit, I.; Franitza, S.; Grabovsky, V.; Slav, M. M.; 
Nagler, A.; Lider, O.; Alon, R.; Zipori, D.; Lapidot, T. The Chemokine SDF-1 Activates 
the Integrins LFA-1, VLA-4, and VLA-5 on Immature Human CD34(+) Cells: Role in 
Transendothelial/Stromal Migration and Engraftment of NOD/SCID Mice. Blood 2000, 
95, 3289-3296. 
7. van Buul, J. D.; Voermans, C.; van Gelderen, J.; Anthony, E. C., van der Schoot, C. 
E.; Hordijk, P. L. Leukocyte-Endothelium Interaction Promotes SDF-1-Dependent 
Polarization of CXCR4. J Biol Chem 2003, 278, 30302-30310. 
8. Voermans, C.; Gerritsen, W. R.; von dem Borne, A. E.; van der Schoot, C. E. Increased 
Migration of Cord Blood-Derived CD34+ Cells, As Compared to Bone Marrow and 
Mobilized Peripheral Blood CD34+ Cells Across Uncoated or Fibronectin-Coated Filters. 
Exp Hematol 1999, 27, 1806-1814. 
9. Petit, I.; Jin, D.; Rafii, S. The SDF-1-CXCR4 Signaling Pathway: A Molecular Hub 
Modulating Neo-Angiogenesis. Trends Immunol 2007, 28, 299-307. 
10. Zhao, W.; Ankrum, J.; Sarkar, D.; Kumar, N.; Teo, W. S.; Karp, J. M. Stem Cell Homing 
to Sites of Injury and Inflammation. In Stem Cells and Revascularization Therapies; 




11. Middleton, J.; Patterson, A. M.; Gardner, L.; Schmutz, C.; Ashton, B. A. Leukocyte 
Extravasation: Chemokine Transport and Presentation by the Endothelium. Blood 2002, 
100, 3853-3860.  
12. Cheng, Z.; Ou, L.; Zhou, X.; Li, F.; Jia, X.; Zhang, Y.; Liu, X.; Li, Y.; Ward, C. A.; 
Melo, L. G.; Kong, D. Targeted Migration of Mesenchymal Stem Cells Modified with 
CXCR4 Gene to Infarcted Myocardium Improves Cardiac Performance. Mol Ther 2008, 
16, 571-579. 
13. Wynn, R .F.; Hart, C. A.; Corradi-Perini, C.; O' Neill,  L.; Evans, C. A.; Wraith, J. 
E.; Fairbairn, L. J.;  Bellantuono, I. A Small Proportion of Mesenchymal Stem Cells 
Strongly Expresses Functionally Active CXCR4 Receptor Capable of Promoting 
Migration to Bone Marrow. Blood 2004, 104, 2643-2645. 
14. Potapova, I. A.; Brink, P. R.; Cohen, I. S.; Doronin, S. V. Culturing of Human 
Mesenchymal Stem Cells as Three-Dimensional Aggregates Induces Functional 
Expression of CXCR4 that Regulates Adhesion to Endothelial Cells. J Biol Chem 2008, 
283, 13100-13107. 
15. Cao, Z.; Zhang, G.; Wang, F.; Liu, H.; Liu, L.; Han, Y.; Zhang, J.; Yuan, J. Protective 
Effects of Mesenchymal Stem Cells with CXCR4 Up-Regulation in a Rat Renal 
Transplantation Model. PLoS One 2013, 8, e82949. 
16. Zhang, D.; Fan, G. C.; Zhou, X.; Zhao, T.; Pasha, Z.; Xu, M.; Ashraf, M.; Wang, Y. 
Over-expression of CXCR4 on Mesenchymal Stem Cells Augments Myoangiogenesis in 
the Infarcted Myocardium. J Mol Cell Cardiol 2008, 44, 281-282. 
17. Goldring, C. E.; Duffy, P. A.; Benvenisty, N.; Andrews, P. W.; Ben-David, U.; Eakins, 
R.; French, N.; Hanley, N. A.; Kelly, L.; Kitteringham, N. R.; Kurth, J.; Laverty, H.; 
McBlane, J.; Narayanan, G.; Patel, S.; Reinhardt, J.; Rossi, A.; Sharpe, M.; Park, B. K. 
Assessing the Safety of Stem Cell Therapeutics. Cell Stem Cell 2011, 8, 618-628. 
18. Mavilio, F.; Pellegrini, G.; Ferrari, S.; Di Nunzio, F.; Di lorio E.; Recchia, A.; Maruggi, 
G.; Ferrari, G.; Provasi, E.; Bonini, C.; Capurro, S.; Conti, A.; Magnoni, C.; Giannetti, 
A.; De Luca, M. Correction of Junctional Epidermolysis Bullosa by Transplantation of 
Genetically Modified Epidermal Stem Cells. Nat Med 2006, 12, 1397-1402. 
19. Liu, X.; Duan, B.; Cheng, Z.; Jia, X.; Mao, L.; Fu, H.; Che, Y.; Ou, L.; Liu, L.; Kong, D. 
SDF-1/CXCR4 Axis Modulates Bone Marrow Mesenchymal Stem Cell Apoptosis, 
Migration and Cytokine Secretion. Protein Cell 2011, 2, 845-854. 
20. Jones, G. N.; Moschidou, D.; Lay, K.; Abdulrazzak, H.; Vanleene, M.; Shefelbine, S. J.; 
Polak, J.; de Coppi, P.; Fisk, N. M.; Guillot, P. V. Upregulating CXCR4 in Human Fetal 
59 
 
Mesenchymal Stem Cells Enhances Engraftment and Bone Mechanics in a Mouse Model 
of Osteogenesis Imperfecta. Stem cells Transl Med 2012, 1, 70-78.  
21. Li, M.; Sun, X.; Ma, L.; Jin, L.; Zhang, W.; Xiao, M.; Yu, Q. SDF-1/CXCR4 Axis 
Induces Human Dental Pulp Stem Cell Migration Through FAK/PI3K/Akt and GSK3β/β-
Catenin Pathways. Sci Rep 2017, 7, 40161. 
22. Perdoni, C.; McGrath, J. A.; Tolar, J. Preconditioning of Mesenchymal Stem Cells for 
Improved Transplantation Efficacy in Recessive Dystrophic Epidermolysis Bullosa. Stem 
Cell Res Ther 2014, 5, 121. 
23. Huang, J.; Zhang, H.; Yu, Y.; Chen, Y.; Wang, D.; Zhang, G.; Liu, J.; Sun, Z.; Sun, D.; 
Lu, Y.; Zhong, Y. Biodegradable Self-Assembled Nanoparticles of Poly(D,L-lactide-co-
glycolide)/Hyaluronic Acid Block Copolymers for Target Delivery of Docetaxel to 
Breast Cancer. Biomaterials 2014, 35, 550-566. 
24. Du, X.; Li, Y.; Xia, Y. L.; Ai, S. M.; Liang, J.; Sang, P.; Ji, X. L.; Liu, S. Q. Insights into 
protein-ligand interactions: mechanisms, models, and methods. Int J Mol Sci 2016, 17, 
144.  
25. Watters, O.; O’Connor, J. J. A Role for Tumor Necrosis Factor-α in Ischemia and 
Ischemic Preconditioning. J Neuroinflammation 2011, 8, 87. 
26. Lesley, J.; Hascall, V. C.; Tammi, M.; Hyman, R. Hyaluronan Binding by Cell Surface 
CD44. J Biol Chem 2000, 275, 26967-26975.  
27. Israelachvili, J. N. Van der Waals Forces Between Particles and Surfaces. In 
Intermolecular and Surface Forces, 3rd Ed.; Israelachvili, J. N., Ed.; Academic Press: 
Santa Barbara, 2011; pp 253-289. 
28. Park, Y.; Huang, R.; Corti, D. S.; Franses, E. I. Colloidal Dispersion Stability of 
Unilamellar DPPC Vesicles in Aqueous Electrolyte Solutions and Comparisons to 
Predictions of the DLVO Theory. J Colloid Interface Sci 2010, 342, 300-310. 
29. Israelachvili, J. N. Electrostatic Forces Between Surfaces in Liquids. Intermolecular and 
Surface Forces, 3rd Ed.; Israelachvili, J. N., Ed.; Academic Press: Santa Barbara, 2011; 
pp 291-340. 
30. Holmes, W. D.; Consler, T. G.; Dallas, W. S.; Rocque, W. J.; Willard, D. H. Solution 




31. Chamberlain, G.; Smith, H.; Rainger, G. E.; Middleton, J. Mesenchymal Stem Cells 
Exhibit Firm Adhesion, Crawling, Spreading and Transmigration Across Aortic 
Endothelial Cells: Effects of Chemokines and Shear. PLoS ONE 2011, 6, e25663. 
32. Teo, G. S.; Yang, Z.; Carman, C. V.; Karp, J. M.; Lin, C. P. Intravital Imaging of 
Mesenchymal Stem Cell Trafficking and Association with Platelets and Neutrophils. 
Stem Cells 2015, 33, 265-277.  
33. Naaldijk, Y.; Johnson, A. A.; Ishak, S.; Meisel, H. J.; Hohaus, C, Stolzing A. Migrational 
changes of mesenchymal stem cells in response to cytokines, growth factors, hypoxia, 
and aging. Exp Cell Res 2015, 338, 97-104. 
34. Bura, A.; Planat-Benard, V.; Bourin, P.; Silvestre, J. S.; Gross, F.; Grolleau, J. L.; Saint-
Lebese, B.; Peyrafitte, J. A.; Fleury, S.; Gadelorge, M.; Taurand, M.; Dupuis-Coronas, S.; 
Leobon, B.; Casteilla, L. Phase I Trial: The Use of Autologous Cultured Adipose-Derived 
Stroma/Stem Cells to Treat Patients with Non-Revascularizable Critical Limb Ischemia. 
Cytotherapy 2014, 16, 245–257. 
35. Kaszuba, M.; Corbett, J.; Watson, F. M.; Jones, A. High-Concentration Zeta Potential 
Measurements Using Light-Scattering Techniques. Philos Trans A Math Phys Eng Sci 











CHAPTER 3: PROTECTING MESENCHYMAL STEM CELLS FROM OXIDATIVE 
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3.2 Introduction  
 Mesenchymal stem cells (MSCs) are promising medicine for the treatment of acute and 
chronic diseases as well as tissue defects because of their innate ability to secrete numerous 
therapeutic factors1-3. Low therapeutic efficacy due to poor survival of the transplanted cells in 
the injured tissues remains as the largest obstacle in stem cells therapy4. Cell tracking studies 
using positron emission tomography showed low retention of the transplanted mesenchymal 
stem cells (i.e.~6%) in the porcine ischemic heart muscle after 10 days of post injection5. 
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Similarly, in murine models of hindlimb ischemia using bioluminescence imaging, only a small 
portion of mesenchymal stem cells survived after transplantation6. 
This impaired therapeutic activity of mesenchymal stem cells at the injured tissues is 
often related to the abnormally high oxidative stress that triggers cell apoptosis. In response to 
hypoxia arising from ischemia injury, the electron transport chain in mitochondria of residential 
cells undergoes conformational changes which facilitate the leakage of electrons7-9. This in turn 
increases the reduction of molecular oxygen to superoxide anion and dismutation to hydrogen 
peroxide (H2O2)
9,10. H2O2 permeates into cells and can react with ferrous iron in cytoplasm to 
produce hydroxyl radical, the most reactive form of radical10-12. These reactive oxygen species 
(ROS) are unstable, thus react with the biological molecules inside the cells12, 13.   
As an innate defense mechanism against ROS-induced damage, cells utilize antioxidant 
enzymes such as glutathione peroxidases and catalases for the conversion of H2O2 into water and 
oxygen12,14. Overproduction of ROS in the injured tissues can overwhelm the intrinsic 
antioxidant capability of cells and result in apoptosis when the free radicals irreversibly 
inactivate the intracellular biological molecules14. In the case of MSCs, studies have revealed 
that H2O2 induces apoptosis via the endoplasmic reticulum and mitochondrial pathways activated 
by protein kinases Jun N-terminal kinase and p3815. Consequently, the transplanted stem cells 
would not be able to secrete the desired therapeutic cytokines and growth factors. 
 To improve the survival of these stem cells at the injured tissues, efforts have been made 
to precondition the cells with antioxidants agents in vitro before transplantation. Preconditioning 
of cells entails cellular incubation in culture media supplemented with the antioxidants of 
interest16. Epigallocatechin gallate (EGCG), which is naturally derived from green tea leaves, is 
one promising antioxidant17,18. When exposed to H2O2 solution, MSCs pre-treated with EGCG 
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exhibited significantly lower intracellular oxidative stress and higher viability than those without 
the EGCG pretreatment17. EGCG helps cells mitigate oxidative stress by oxidizing the D ring of 
its galloyl group and increasing the activity of the antioxidant enzymes in the cells17,18. However, 
cell culture media often contains animal-derived products (e.g. fetal or horse serum) and may 
elicit unwanted xenogeneic immune responses.  
 In Chapter 2, we have developed nanoparticles that can adhere to stem cells and release 
bioactive molecules via passive diffusion. The phenotypic and secretion activities of transplanted 
stem cells were consequently regulated in situ. The nanoparticles were prepared from a block 
copolymer of poly(D,L-lactide-co-glycolide) and CD44-binding hyaluronic acid (denoted as 
PLGA-b-HA). Tethering of nanoparticles releasing antioxidants such as EGCG to the surface of 
mesenchymal stem cells could be a plausible strategy to protect the cells from the oxidative 
effects in the injured tissues. Particularly, the success in rescuing stem cells from the H2O2-
induced death would depend on the capability of the particles to actively release antioxidants in 
response to the level of H2O2. 
 To this end, we hypothesized that nanoparticles devised to anchor to stem cell surface 
and discharge antioxidant cargos in the presence of H2O2 would prolong cellular survival and 
maintain therapeutic activity of MSCs in the transplanted site (Figure 3.1). We examined this 
hypothesis by encapsulating EGCG molecules into PLGA-b-HA nanoparticles loaded with 
MnO2 nanosheets, termed as active anti-oxidizing nanoparticles. At elevated levels of H2O2, 
MnO2 nanosheets served to increase the internal pressure of particles by decomposing the H2O2 
to O2 gas
19. The pressure increment acts as a pump that would release the EGCG molecules. 
These particles were tethered to adipose tissue-derived MSCs.   
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 Specifically, we evaluated the release rate of EGCG from the active anti-oxidizing 
nanoparticles in media supplemented with H2O2. We also assessed the spatial distribution and 
binding affinity of these particles to the surface of stem cells. We next examined the extent to 
which these particles modulated the metabolic activity, the secretion activity, the intracellular 
oxidative stress level, and the glutathione peroxidase activity of the stem cells in an oxidative 
environment. Finally, MSCs exposed to H2O2 were transplanted on the chick chorioallantoic 
membrane to evaluate the angiogenic potential of the stem cells.  
 
3.3 Results  
3.3.1 Physical Characterization of the Active Anti-Oxidizing Nanoparticles  
The active anti-oxidizing nanoparticles were fabricated via the double emulsification. An 
aqueous mixture of EGCG and MnO2 nanosheets was introduced to a mixture of 
dimethylformamide and dichloromethane dissolved with the PLGA-b-HA. The emulsion was 
then transferred to another aqueous phase to give the second emulsion. Subsequent evaporation 
of the organic phase in the second emulsion yielded the anti-oxidizing nanoparticles. The 
presence of MnO2 nanosheets in the particles was confirmed with the transmission electron 
microscopic (TEM) images (Figure 3.2). Particles with MnO2 nanosheets (Figure 3.2A-ii) 
appeared darker and denser than the nanoparticles without MnO2 nanosheets (Figure 3.2A-i). 
The average diameter of the active anti-oxidizing nanoparticles was 70 ± 10 nm as determined 
from the TEM images (Figure 3.2A-iii).  
In phosphate buffered saline, both particles with and without the MnO2 nanosheets 
displayed a similar release profile (Figure 3.2B-i).  We further examined the ability of the 
particles to release EGCG in response to an elevated H2O2 level by incubating the particles in 
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200 µM H2O2 solution. The release rate of EGCG was quantified by measuring the concentration 
of EGCG in the release medium at the designated time points and taking ratio with respect to the 
total concentration of EGCG in the particles.  By the first hour, the release rate of EGCG was 
1.5-fold faster with the presence of MnO2 nanosheets in the particles (Figure 3.2B-ii). The 
particles loaded with MnO2 nanosheets released 100% of EGCG within 24 h. In contrast, 
nanoparticles without MnO2 nanosheets released about 80% of the encapsulated EGCG and 
displayed similar release profile as those of particles incubated in media free of H2O2. 
In parallel, we monitored the rate of change in the H2O2 concentration in media 
containing free MnO2 nanosheets, and the PLGA-b-HA nanoparticles with and without the 
MnO2 nanosheets (Figure 3.2C). The concentration of H2O2 in the media was measured using a 
colorimetric assay kit that quantifies the amount of purple product formed from the complexation 
reaction between Fe3+ and the xylenol orange provided. The concentration of Fe3+, which is 
produced from the redox reaction between Fe2+ and H2O2, is proportional to the concentration of 
H2O2. Using Figure 3.2C, we then extrapolated the increment of internal pressure of particles due 
to O2 gas generation (∆PO₂) from the H2O2 decomposition (Figure 3.2D). MnO2 nanosheets 
catalyzed the decomposition of H2O2 to yield water and O2 gas as follows: 
 
Assuming an ideal gas behavior to the O2 molecules generated, we approximated the O2 pressure 
using Eq. (1).  
                                                                                                                                   (1) 
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Where  is the number of moles of O2 generated,  is the volume of O2 gas equivalent to the 
total volume of nanoparticles made from 10 mg of PLGA-b-HA polymer, R is the universal gas 
constant (8.314 Jmol-1K-1) and T is the working temperature at 298 K. Approximating the density 
of PLGA-b-HA polymer to be 1.3 g/mL, was calculated to be 7.46 x 10-9 m3. 
Based on the stoichiometry for the decomposition reaction of H2O2,  
                                                                                                                                (2) 
Where is the number of moles of H2O2 consumed.  
The increase in O2 pressure in the particles due to the H2O2 decomposition (∆PO₂) is given in Eq.  
(3).  
                                                                                 (3) 
Where  is the concentration of dissolved O2 in water at 25 °C (i.e. 8.2 mg/L). 
Accordingly, ∆PO₂ at 24 h was 8-fold higher for nanoparticles containing MnO2 nanosheets (19.6 
kPa) than that without the MnO2 nanosheets (2.5 kPa). 
 
3.3.2 PLGA-b-HA Nanoparticles Adhere to Cellular Surface Better than PLGA 
Nanoparticles  
We tethered the surface of MSCs with fluorescently-labeled nanoparticles by mixing the 
cells with the particles in suspension for 15 min at room temperature prior to centrifugation for 
confocal imaging (Figure 3.3A). Both PLGA particles and PLGA-b-HA particles were labeled 
by encapsulating bovine albumin conjugated with Rhodamine B. Successful adhesion of the 
particles onto stem cells was identified by the co-localization of red fluorescence from particles 
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and the green fluorescence from cell surface membrane (Figure 3.3B). A higher intensity of red 
fluorescence was observed on the surface membrane of cells tethered with PLGA-b-HA 
nanoparticles (Figure 3.3B).  
 
3.3.3 Active Anti-Oxidizing Nanoparticles Retain Metabolic Activity of MSCs in an 
Oxidative Environment  
We next examined the metabolic activity of MSCs in an H2O2-rich environment. Stem 
cells were tethered with the nanoparticles and were encapsulated in collagen gel prior to 
incubation in a media mixed with 200 M H2O2 for 2 h (Figure 3.4A). Metabolically active cells 
were identified with positive staining by the 2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-
Tetrazolium-5-Carboxanilide (XTT) assay. Stem cells tethered with nanoparticles loading EGCG 
and MnO2 nanosheets demonstrated higher metabolic activity than untethered cells and cells 
tethered with blank nanoparticles (Figure 3.4B). This protective effect was more pronounced on 
Day 4, with a 1.4-fold higher metabolic activity than the other two conditions (Figure 3.4B).  
The morphology of MSCs was imaged under an optical microscope on Day 4 (Figure 
3.4C). In the H2O2-free media, untethered cells exhibited an elongated shape and extended 
towards neighboring cells (Figure 3.4C-i). In contrast, the majority of the untethered cells and 
those tethered with blank particles were in a spherical morphology after the exposure to H2O2 for 
2 h and incubation in fresh culture media over the next 3 days (Figures 3.4C-ii and 3.4C-iii). A 
smaller fraction of spherical cells was seen in those tethered with particles loading EGCG only 
(Figure 3.4C-iv). Most of the cells tethered with nanoparticles loading EGCG and MnO2 




3.3.4 Active Anti-oxidizing Nanoparticles Retain Proangiogenic Factor-Secretion Activity 
of  MSCs in an Oxidative Environment 
We then evaluated the secretory activity of MSCs in an oxidative environment by 
measuring the concentration of vascular endothelial growth factor (VEGF) in the conditioned 
media (Figure 3.5A). Stem cells cultured in the H2O2–free media secreted comparable levels of 
VEGF across all conditions on Day 1 and Day 4 (Figure 3.5B). Thus, MSCs in all conditions 
displayed an increase in the VEGF secretion level.  
On the contrary, both untethered cells and those tethered with blank nanoparticles 
secreted 3-fold and 60-fold lower VEGF levels on Day 1 and Day 4, respectively, following the 
2 h exposure to 200 µM H2O2 than those cultured in the H2O2-free media (Figure 3.5B). 
Additionally, these two groups undertook a drastic decrease in the secretion level of VEGF by 4-
fold throughout 4 days of cell culture (Figure 3.5B). In contrast, on Day 1, cells tethered with 
nanoparticles loading EGCG and MnO2 nanosheets secreted 1.4-fold higher mass of VEGF than 
those tethered with nanoparticles without MnO2 nanosheets (Figure 3.5B). This difference 
between the two conditions became more significant on Day 4 by a fold-change of 5.  
 
3.3.5 Active Anti-oxidizing Nanoparticles Tethered to MSCs Reduce Intracellular 
Oxidative Stress and Enhance Activity of Glutathione Peroxidase  
 We studied the mechanism by which the active anti-oxidizing nanoparticles reduced the 
impacts of H2O2 on MSCs by analyzing the intracellular oxidative stress level and the 
antioxidant enzyme glutathione peroxidase (GPx) activity. The intracellular oxidative stress level 
was examined with CellROX® Green which emits green fluorescence upon reactive oxygen 
species-induced oxidation and subsequently binds to DNA. Stem cells incubated in the media 
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containing 200 µM H2O2 for 2 h displayed an increased fluorescence intensity of CellROX® 
Green (Figures 3.6A and 3.6B). On the other hand, nanoparticles loading EGCG only alleviated 
the positive green fluorescence in cells by 1.5-fold as compared with the untethered cells. A 
more drastic decrease by 3-fold in the fluorescence intensity was observed in cells tethered with 
nanoparticles loading EGCG and MnO2 nanosheets (Figures 3.6A and 3.6B). 
The activity of GPx in MSCs was assessed following exposure to either culture media or 
media containing 200 µM H2O2 for 2 h. The GPx level was measured by quantifying the 
depletion rate of dihydronicotinamide-adenine dinucleotide phosphate (NADPH) during the 
redox reaction of glutathione. To ensure that the value of GPx activity is independent of the 
fraction of metabolically active cells, we normalized it with respect to the number of 
metabolically active cells in each condition. Untethered stem cells displayed similar GPx activity 
in both H2O2-free media and H2O2-media (Figure 3.6C). On the contrary, in the H2O2-media, 
cells tethered with particles loading EGCG only and those tethered with particles loading EGCG 
and MnO2 nanosheets showed a 1.3-fold higher GPx level than the untethered stem cells (Figure 
3.6C).  
 
3.3.6 Active Anti-oxidizing Nanoparticles Tethered to MSCs Enhance Vascularization  
Finally, we examined the extent to which the active anti-oxidizing nanoparticles 
improved the angiogenic potential of H2O2-exposed MSCs using the chick chorioallantoic 
membrane (CAM). Collagen gels encapsulating stem cells were embedded onto the membrane 
and incubated over 6 days before analyzing the extent of mature vasculature formation at the site 
implanted with the collagen gel (Figure 3.7A). The mature blood vessels in the CAM were 
identified with positive staining of α-smooth muscle actin (red arrows in Figure 3.7B). Control 
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conditions included the cell-free collagen gel (Figure 3.7B-i), the collagen gel encapsulating 
untethered stem cells (Figure 3.7B-ii), and the collagen gel encapsulating stem cells tethered 
with nanoparticles loading EGCG only (Figure 3.7B-iii). Compared with these three conditions, 
collagen gels encapsulating stem cells tethered with nanoparticles loading EGCG and MnO2 
nanosheets doubled the number α-smooth muscle actin-positive blood vessels (Figures 3.7B-iv 
and 3.7C). Furthermore, ~40% of the total number of vessels exhibited cross-sectional areas of 
larger than 500 µm² (Figure 3.7D). On the contrary, the majority of blood vessels in CAM 
implanted with collagen gel containing with and without stem cells had cross-sectional areas 
between 50-200 µm² (i.e. ~50-60% of total number of blood vessels). Stem cells tethered with 
nanoparticles loading EGCG only yielded blood vessels with intermediate cross-sectional areas 
of 200-500 µm² (Figure 3.7D).  
 
3.4 Discussion 
The results of this study have successfully demonstrated a new facile approach that 
protects MSCs from H2O2-induced oxidative damage and subsequently maintains their 
angiogenic potential. This approach encompasses the tethering of stem cells with PLGA-b-HA 
nanoparticles that can release epigallocatechin gallate (EGCG), a model antioxidant, in response 
to elevated levels of H2O2. The nanoparticles, named as active anti-oxidizing nanoparticles, were 
loaded with EGCG and Manganese (IV) oxide (MnO2) nanosheets.  
The active anti-oxidizing nanoparticles were prepared by a simple double-emulsification. 
The presence of MnO2 nanosheets in these nanoparticles was confirmed with the TEM images 
that showed an increased dark contrast as compared to the blank nanoparticles. The MnO2 
nanosheets in the particles increased the release rate of EGCG exclusively in the presence of 
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H2O2. On the other hand, the rate of EGCG release from particles without the MnO2 nanosheets 
did not show any dependency on the H2O2 level. This result affirms that these particles can 
discharge EGCG in response to the H2O2 level. In this study, we used the media containing 200 
µM H2O2 to create a physiologically relevant oxidative environment. This H2O2 concentration 
falls within the pathophysiological relevant levels of H2O2 in ischemia
20, 21.  
We propose that the stimulus-responsive release of EGCG results from the O2 generation 
caused by the decomposition of H2O2. The MnO2 nanosheets catalyzed the H2O2 decomposition 
likely through a series of chain reactions involving redox couple Mn4+/Mn3+ and the formation of 
radical HO2• that propagates the conversion of H2O2 into water and O2 gas
22.  The resulting O2 
gas increases the internal pressure of the particles, thereby forcing the EGCG molecules out19.  
Amongst the numerous oxides of metal including iron and cobalt, manganese oxide demonstrates 
the highest reactivity in promoting the H2O2 decomposition, and thus, generating the largest 
amount of O2 gas within a given period
23.  
The highlight of this study lies in the approach of tethering the surface of stem cells with 
the active anti-oxidizing nanoparticles capable of retaining their therapeutic activity in a harsh 
oxidative environment in situ. The PLGA-b-HA nanoparticles bound to the surface of MSCs via 
specific bonds between CD44 of the stem cells and HA of the particles. The limited attachment 
of PLGA nanoparticles on the surface of MSCs confirms the critical role of specific ligand (HA)-
receptor (CD44) interaction for the cell surface tethering.   
The active anti-oxidizing nanoparticles tethered to cells could successfully protect the 
cells from the detrimental effects of H2O2. MSCs were seeded in a collagen gel to mimic the 
tissue microenvironment where stem cells are transplanted24. Cells were cultured in an oxidative 
media containing 200 µM H2O2 for 2 h. The active anti-oxidizing nanoparticles improved the 
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metabolic activity of cells by 1.2-fold as compared to nanoparticles loading EGCG only, due to 
the enhanced release of EGCG within the first 2 h. By Day 4, the protective role of these active 
anti-oxidizing nanoparticles became more significant with a 1.3-fold higher metabolic activity 
than that of nanoparticles loading EGCG only.  
Although the media containing 200 µM H2O2 was replaced with fresh culture media after 
2 h, it is likely that the cells could not recover from the oxidative damage, and thus failed to 
proliferate thereafter. Additionally, we suggest that the elevated internal pressure of the active 
anti-oxidizing nanoparticles did not drop immediately and sustained the accelerated release of 
EGCG over the next 4 days. Therefore, cells tethered with the active anti-oxidizing nanoparticles 
could produce daughter cells through continued cell division, thereby widening the differences in 
the number of metabolically active cells between conditions.  
This study also presents a positive correlation between the metabolic activity and pro-
angiogenic factor secretion activity of stem cells. Since MSCs secrete soluble VEGF25-27, the 
concentration of this growth factor in the cell culture media would concur with the level of 
cellular secretion. On Day 1 and Day 4 after the 2 h exposure to H2O2 solution, stem cells 
tethered with the active anti-oxidizing nanoparticles exhibited higher metabolic activity and 
VEGF secretion levels than the control conditions. These controls include the untethered stem 
cells, stem cells tethered with blank nanoparticles, and stem cells tethered with nanoparticles 
loading EGCG only. Intriguingly, the metabolic activity of both untethered stem cells and stem 
cells tethered with blank nanoparticle did increase over the next three days. However, their 
secretion activity plummeted instead. Such observation suggests that cells, although appeared to 
be metabolically active, were not in the conducive state to secrete the pro-angiogenic factor. On 
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the other hand, metabolically active cells of those tethered with the active anti-oxidizing 
nanoparticles remained in a good condition to secrete VEGF in an oxidative environment.  
The entry of H2O2 into MSCs and the subsequent accumulation would raise the 
intracellular oxidative stress level. Accordingly, untethered stem cells experienced an elevated 
oxidative stress level following exposure to H2O2 for 2 h, as reflected by the strong green 
fluorescence intensity of CellROX® Green, CellROX® Green remains non-fluorescent until it 
gets oxidized by reactive oxygen species (e.g. H2O2) in the cells. Therefore, the fluorescence 
intensity of CellROX® Green is proportional to the level of oxidative stress.  In contrast, stem 
cells tethered with particles loading EGCG only and those tethered with the active anti-oxidizing 
nanoparticles showed a limited increase in the oxidative stress level. We attribute this 
observation to the improved activity of the antioxidant enzyme, GPx, in these cells.  
In an oxidative intracellular environment, GPx catalyzes the reduction of H2O2 to water 
while oxidizing reduced monomeric glutathione (GSH) to glutathione disulfide (GSSG) as 
follows28: 
 
With a higher activity of GPx per metabolically active cell, more H2O2 molecules in the cells get 
depleted and, in turn, reduces the level of intracellular oxidative stress. Interestingly, the 
enhanced release of EGCG from the active anti-oxidizing nanoparticles did not increase the 
activity of GPx in stem cells as compared with those tethered with nanoparticles loading EGCG 
only. However, we observed a lower green fluorescence of CellROX® Green in cells tethered 
with the active anti-oxidizing nanoparticles than cells tethered with particles loading EGCG 
only. Taken together, we propose that the MnO2 nanosheets in the active anti-oxidizing particles 
depleted the H2O2 surrounding the cells such that a smaller number of H2O2 molecules entered 
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and accumulated in the cells. These mechanistic studies implicate a collaborative effort between 
the EGCG molecules and the MnO2 nanosheets in improving cellular survival and retaining their 
therapeutic potential an oxidative environment.  
The positive correlation between cellular metabolic activity and secretion activity of pro-
angiogenic factors established in vitro was also observed in vivo. CAM implanted with the 
collagen gel encapsulating stem cells tethered with the active anti-oxidizing nanoparticles 
exhibited the highest number of mature blood vessels on Day 6-post implantation. The enhanced 
cellular metabolic activity led to an increased collective amount of VEGF secreted by the stem 
cells. This, in turn, stimulated the growth of new blood vessels and the maturity of existing 
vessels, as reflected by the formation of blood vessels with cross-sectional areas of over 500 
µm2. On the contrary, the lower metabolic activity and VEGF secretion levels of untethered stem 
cells and stem cells tethered with blank particles yielded a reduced number and size of blood 
vessels in the CAMs.     
To the best of our knowledge, this is the first report on tethering of cellular surface with 
active anti-oxidizing nanoparticles capable of retaining the secretion activity of stem cells in an 
oxidative environment. Previous efforts focused on increasing the resilience of stem cells against 
oxidative stress by transfecting them with anti-apoptotic genes of the protein kinase B (AKT)29 
or heat shock proteins including Hsp-2030. Pretreatment of stem cells with a cocktail of 
antioxidants in culture media before transplantation is another strategy31. In contrast, our 
approach improves the intrinsic anti-oxidizing activity of stem cells and, at the same time, 
reduces the H2O2 level at the transplanted sites and its corresponding oxidative impacts in the 
stem cells. More importantly, the short duration of tethering the stem cells with our nanoparticles 
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In conclusion, this study presented a simple in situ approach to protect therapeutic stem 
cells and to maintain their secretion activity in an oxidative environment. PLGA-b-HA 
nanoparticles containing antioxidant EGCG and MnO2 nanosheets were tethered onto the surface 
of stem cells via HA-CD44 interactions. When exposed to sub-lethal physiopathologically 
relevant concentration of H2O2, majority of these cells remained metabolically active and 
proliferated. The intracellular oxidative stress in the stem cells also declined to a level 
comparable to those without H2O2 exposure. Mechanistically, MnO2 nanosheets reduced the 
concentration of H2O2 by decomposing it to O2 gas which in turn accelerated the release of the 
entrapped EGCG. EGCG improved the activity of glutathione peroxidase in the stem cells which 
catalyzed the reduction of H2O2. Consequently, with the higher fraction of metabolically active 
stem cells, more pro-angiogenic VEGF was secreted by the cells collectively, and thus, a greater 
extent of blood vessel maturation was observed in the chick chorioallantoic membranes. Blood 
flow restoration in ischemia and the therapeutic efficacy of these stem cells need to be verified in 
future studies. Nevertheless, the results in this study will broadly serve to improve the angiogenic 







3.6 Materials and Methods 
3.6.1 Materials 
All chemicals were obtained from Sigma-Aldrich (U.S.A.), and used as received unless 
specified. Hyaluronic acid (HA) of molecular weights 10kDa was purchased from Lifecore 
Biomedical (U.S.A.). PLGA with an acid end group and molecular weights ranging from 6,000 
to 10,000 g/mol (ratio of lactic: glycolic =50:50) was bought from LACTEL Absorbable 
Polymers, DURECT (U.S.A). Bovine collagen solution (PureCol®, Type 1) was purchased from 
Advanced Biomatrix. The reconstituting solution for gelation of collagen was formulated as a 
mixture of sodium bicarbonate (0.26 M), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
(HEPES, 0.2 M) and sodium hydroxide (0.04 N). Sodium 2,3,-bis(2-methoxy-4-nitro-5-
sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-tetrazolium inner salt (XTT) cell proliferation kit 
and CellROX® Green Reagent were obtained from Trevigen (U.S.A.) and ThermoFisher 
Scientific (U.S.A.), respectively. DAPI was purchased from InvitrogenTM (U.S.A.). Rhodamine 
B conjugated bovine serum albumin (BSA-Rhodamine B) was prepared by reacting 1 mg/mL of 
Rhodamine B isothiocyanate (dissolved in DMSO) with 6 mg/mL of BSA (dissolved in 0.1 M 
sodium bicarbonate buffer, pH 9.2). BSA-Rhodamine B was purified via dialysis against water 
and lyophilized prior to usage. All experiments involving BSA-Rhodamine B were performed in 
the dark.  
 
3.6.2 Cell Culture 
Human adipose-derived mesenchymal stem cells were purchased from Lonza (U.S.A.) 
and cultured in Minimum Essential Medium Alpha Medium (Corning, U.S.A.) containing 2 mM 
L-Glutamine and sodium pyruvate (Lonza, U.S.A) supplemented with 10% fetal bovine serum 
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(FBS, Life Technologies, U.S.A.), 100 U/mL penicillin (Lonza, U.S.A.) and 100 µg/ml 
streptomycin (Lonza, U.S.A.) at 37 °C in 5% CO2 atmosphere. All cellular experiments were 
conducted using adipose-derived mesenchymal stem cells of passage 6 or lower. Culture media 
without sodium pyruvate was used whenever hydrogen peroxide was involved. 
 
3.6.3 Synthesis of PLGA-b-HA and Fabrication of Active Anti-Oxidizing Nanoparticles 
Block copolymers of PLGA and HA were synthesized using an end-to-end coupling 
strategy as described in the Methods of Chapter 2. Briefly, N-hydroxysuccinimide-functionalized 
PLGA (120 mg, 1.5 × 10-5 mol) was reacted with amino-functionalized HA (150 mg, 1 × 10-5 
mol) in dimethyl sulfoxide for 48 h at 50 °C under stirring. N, N-diisopropylethylamine (4.4 µL, 
2.5 × 10-5 mol) was charged to the reaction vial. The resulting block copolymer was purified via 
dialysis against deionized water for 48 h before lyophilizing.   
The active anti-oxidizing nanoparticles were fabricated using the double emulsion 
method. Briefly, 10 mg of PLGA-b-HA was dissolved in 0.25 mL of dimethylformamide under 
sonication, and subsequently charged with 0.75 mL of dichloromethane, and sonicated for ~ 1 h. 
MnO2 nanosheets were prepared by dissolving KMnO4 (50 mM, 500 µL) into alginate solution 
(2.0 % w/v in 0.2 M MES buffer at pH 6.0, 500 µL). EGCG (1 mg/mL in 25 mM MnO2 
nanosheets, 200 µL) was added to the organic phase of polymer, and immediately sonicated in an 
ice-bath for 30 sec using a probe-based sonicator (Fisher Scientific Sonic Dismembrator Model 
100, U.S.A.) followed by vortexing for 30 sec (Scientific Industries, Inc, U.S.A.). This probe-
based sonication and vortexing was repeated twice to yield the first emulsion. The second 
emulsion was produced when the first emulsion was introduced to an aqueous polyvinyl alcohol 
(1% v/v PVA), and probe-based sonicated in ice-bath followed by vortexing for three rounds. 
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The resulting active anti-oxidizing nanoparticles were then magnetic stirred for ~ 4 h at room 
temperature to allow evaporation of organic solvents. They were collected via centrifugation, 
washed once in DI water and used for further studies or lyophilized for 2 days. 
 
3.6.4 Physical Characterization of the Active Anti-oxidizing Nanoparticles 
3.6.4.1 Morphological Analysis  
The morphologies of freshly prepared active anti-oxidizing nanoparticles were analyzed 
by transmission electron microscopy (JEOL 2100 Cryo TEM, U.S.A.) using an acceleration 
voltage of 200 keV. A drop of the nanoparticle solution (10.0 µL) was added onto a carbon film 
200 mesh copper grid (Electron Microscopy Sciences, U.S.A.), and left to dry at room 
temperature overnight.  
 
3.6.4.2 Encapsulation Efficiency of EGCG, in vitro release of EGCG and Reactivity to H2O2 
 Encapsulation efficiency of EGCG in the nanoparticles was quantified by centrifugation 
of the nanoparticles (10 mg/mL) at 12,000 rpm for 5 min at room temperature at the designated 
time points. The absorbance of EGCG in the supernatant was measured at 230 nm using a 
microplate reader (TECAN Infinite® M200 Pro, Switzerland). Three replicates were evaluated. 
A linear curve of absorbance against concentration of EGCG was plotted. The actual mass of 
EGCG encapsulated in the nanoparticles was calculated from the difference between the initial 
feeding mass of 0.2 mg and the mass of EGCG present in the supernatant. The encapsulation 




 The release profile of EGCG was obtained by subjecting the active anti-oxidizing 
nanoparticles and nanoparticles loading EGCG only (10 mg/mL in PBS with 0 or 200 µM H2O2) 
to shaking at 100 rpm at 37 °C. At the designated time points, the particles were centrifuged at 
12,000 rpm for 5 min at room temperature. The supernatant was collected to measure the 
absorbance of EGCG released from the particles at 230 nm. Separately, the concentration of 
H2O2 in the supernatant was quantified by using Pierce™ Quantitative Peroxide Assay Kit 
(Thermo Scientific, U.S.A.) which measures the amount of purple product formed from the 
complexation of Fe3+ and xylenol orange at an absorbance of 560 nm. The concentration of Fe3+, 
which is produced from the redox reaction between Fe2+ and H2O2, is proportional to the 
concentration of H2O2. The particles were then re-suspended with 1 mL of fresh PBS with or 
without the H2O2. 
 
3.6.5 Analysis of Spatial Distribution of PLGA-b-HA Nanoparticles on MSCs 
PLGA-b-HA nanoparticles were fluorescently labeled by loading BSA-Rhodamine B. 
These fluorescently labeled particles (33 mg/mL, 100 µL) were mixed with MSCs (1 × 105 
cells/mL) for 15 min at room temperature. The mixture was subsequently centrifuged to remove 
unbound particles in the supernatant. The cell pellet was then resuspended with PBS and seeded 
immediately on glass slides sandwiched with coverslips for confocal imaging (Carl Zeiss LSM 
700, Germany). The nuclei and plasma membrane of the cells were stained with Hoechst 33342 
(5 µg/mL, Thermo Fisher Scientific, U.S.A.) and DiO (25 ng/ml, Invitrogen, U.S.A.). The 
excitation wavelength (ex) and emission wavelength (em) of each probe were as follows: 
Hoechst 33342 (ex: 350 nm, em: 470 nm), DiO (ex: 480 nm, em: 520 nm), Rhodamine B (ex: 
532 nm, em: 625 nm).  
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3.6.6 Seeding of MSCs in Collagen Gel and Exposure to H2O2 
MSCs were coated with the particles and seeded in collagen gel of composition (Type 1 
collagen: cell suspension in pyruvate free media: reconstitution solution = 8:4:1) in 96-well 
plates at 15, 625 cells/well. Following the gelation of collagen at 37 °C under an atmosphere of 
5% CO2, the cells were either incubated with H2O2 solution (200 µM, 100 µL/well) or pyruvate 
free media for 2 h. The solution was subsequently removed and replaced with fresh medium.  
 
3.6.7 Analysis of Metabolic Activity of MSCs  
The ability of the active anti-oxidizing nanoparticles to maintain the metabolic activity of 
MSCs in H2O2 was assessed through the XTT assay. Following the removal of H2O2 solution in 
3.6.6, XTT assay was either performed immediately or on Days 1 and 4 where 50 µL of XTT 
solution comprising XTT activator and XTT reagent (1: 50 v/v) was added to 100 µL of culture 
medium in each well. The plates were maintained at 37 °C under an atmosphere of 5% CO2 for 3 
h before measuring the absorbance at 490 nm with a reference wavelength of 630 nm. Three 
replicates were tested for each condition. The relative metabolic activity was assessed as the ratio 
of absorbance to that of stem cells without H2O2 solution exposure.  
 The morphology of these MSCs seeded in collagen in the 96-well plates was observed 
under an inverted microscope (Leica DMi1, Germany) installed with imaging software Leica 







3.6.8 Analysis of Secretion Activity of MSCs  
 The ability of MSCs to secrete vascular enodthelial growth factor (VEGF) was 
determined through ELISA. Following 3.5.6,  the cell culture media from each well was 
collected on Days 1 and 4. The volume of the cell culture supernates was monitored visually on a 
daily basis to ensure no/minimal loss. The concentration of VEGF in the supernates was 
quanitifed using a Human DuoSet VEGF enzyme-linked immunosorbent assay (ELISA) kit 
(R&D Systems, U.S.A.). In brief, 96-well plates were incubated with the given Capture 
Antibody (diluted in PBS) for overnight at room temperature. After removal of the Capture 
Antibody and washing of the plates with PBS containing 0.05% Tween 20, Regent Diluent was 
added to the plates to block free binding sites. Diluted supernates and standards (100 µL/well) 
were added to the plates after washing and incubated for 2 h at room temperature.  Following 
thorough washing, biotinylated Detection Antibody (diluted in Regent Diluent) was introduced 
for 2 h before adding Streptavidin conjugated to Horse Radish Peroxidase to each well. Substrate 
Solution comprising H2O2 and tetramethylbenzidine was added subsequently to the plates for 20 
min at room temperature, and was followed by the addition of Stop Solution (2N H2SO4) to 
quench the reaction. The optical density of each well was measured immediately at an 
absorbance wavelength of 450 nm using the microplate reader (TECAN® Infinite M200 Pro, 
Switzerland). A correction wavelength of 570 nm was used to account for optical imperfections.  
 
3.6.9 Analysis of Intracellular Oxidative Stress Level of MSCs 
 The level of oxidative stress in MSCs was assessed using CellROX® Green Reagent. 
Prior to the end of H2O2 exposure in 3.5.6, CellROX® Green Reagent (10 µM) was added to the 
culture media in each well and incubated for 30 min at 37 °C under an atmosphere of 5% CO2. 
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The cells were subsequently fixed with 3.7% formaldehyde for 20 min at room temperature 
before DAPI staining (300 µM) for 20 min at room temperature. The samples were washed with 
PBS and transferred onto clean glass slides gently sandwiched with coverslips for confocal laser 
scanning microscopy (Carl Zeiss LSM 700, Germany). The excitation/emission wavelengths of 
DAPI and CellROX® Green Reagent were 405 nm/435 nm and 488 nm/520 nm, respectively. 
All observations were conducted under the same instrumental settings. ImageJ software was then 
utilized to quantify the mean gray value of CellROX® Green Reagent per stem cell. A minimum 
of 5 individual cells was evaluated per condition.  
 
3.6.10 Analysis of Activity of Glutathione Peroxidase in MSCs  
The activity of glutathione peroxidase (GPx) in the stem cells was examined using a 
Glutathione Peroxidase Activity Colorimetric Assay kit (BioVision. Inc., U.S.A.). MSCs of 
various conditions were seeded in collagen gel at a density of 50,000 cells per well in 24-well 
plates. Following 2 h exposure to H2O2 solution (200 µM, 300 µL/well), the cells were washed 
once with cold PBS and homogenized with hypodermic needles (28G) in cold Assay Buffer 
(BioVision, K762-100-1) on ice. The cell homogenates were collected and centrifuged at 10,000 
g for 15 min at 4°C. The supernatant samples were then collected in cold tubes and stored on ice. 
50 µL of the samples (diluted in cold Assay Buffer) or Assay Buffer (as control) was added into 
each well of 96-well plates before preparation of the Reaction Mix comprising the Assay Buffer, 
NADPH solution, glutathione reductase, and reduced glutathione. 40 µL of the Reaction Mix 
was subsequently added to each well followed by the addition of 10 µL of cumene 
hydroperoxide to start the depletion reaction of GPx (proportional to the concentration of 
NADPH). The optical density (OD340) of NADPH was measured at 340 nm using a microplate 
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reader (TECAN® Infinite M200 Pro, Switzerland). NADPH standard curve was generated by 
plotting the OD340 values against the respective concentration of NADPH (in nmol). An OD340 
higher than 1.0 was obtained by addition of NADPH before adding cumene hydroperoxide and 
remeasured at T1 after adding it to read A1. OD34 was measured again at T2 (from 2 to 35 min) 
to read A2.  The amount of NADPH depletion (B) from T1 to T2 was evaluated as follows: 
 
Where   
The activity of GPx in the samples was expressed as nmol/min/mL= mU/mL and calculated as:  
 
Where V is the pretreated sample volume added to the reaction well (in mL); D is the dilution 
factor in the samples. Three replicates per condition were used to assess the average activity of 
GPx.  
 
3.6.11 Analysis of Angiogenesis Potential of MSCs Using Chick Chorioallantoic Membrane 
 Fertilized chicken eggs (HY-Line W-36) were obtained from the University of Illinois 
Poultry Farm (Urbana, IL). The eggs were incubated at 37 °C under humidity of 5% CO2 
atmosphere for 12 days. Following the initial incubation, a small window (approximately 1.5 cm 
diameter) was created on the egg shell to expose the chick chorioallantoic membrane (CAM). 
MSCs seeded in collagen gel were incubated in media containing 200 µM H2O2 for 2 h before 
implanting onto the CAM: Group 1 for collagen gel without cells, Group 2 for untethered cells, 
Group 3 for cells tethered with nanoparticles containing EGCG only, and Group 4 for cells 
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tethered with the active anti-oxidizing nanoparticles. The window was then resealed with 
adhesive tapes and the eggs were returned to the incubator. After 6 days, the CAM was fixed 
with formalin for 24 h before excising the portion surrounding the collagen gel. The excised 
CAM was subsequently embedded in paraffin and the cross-sections were stained for α-smooth 
muscle actin with diaminobenzidine (DAB) as peroxidase substrate. The immunostained samples 
were visualized with the NanoZoomer slide scanner (Hamamatsu, Japan) amplified using the 
NanoZoomer Digital Pathology (NDP) view software. The number of blood vessels and their 
individual cross-sectional area were manually quantified from two samples per condition.  
 
3.6.12 Statistical Analysis 
All data are expressed as mean  standard deviation. Statistical analysis between two 
experimental groups was performed by the Student’s t-test. A value of p < 0.05 indicated a 











3.7 Figures  
 
Figure 3.1. In situ protection of mesenchymal stem cells (MSCs) in a H2O2-rich environment. 
Stem cells are tethered with PLGA-b-HA nanoparticles containing antioxidant EGCG and MnO2 
nanosheets, termed as active anti-oxidizing nanoparticles, via HA-CD44 interactions. MnO2 
nanosheets catalyzes the decomposition of H2O2 within the particles, and the O2 gas generated 
increases the internal pressure. This pushes the EGCG molecules out of the particles, facilitating 






Figure 3.2. Physical characterization of the active anti-oxidizing nanoparticles. (A) 
Transmission electron microscopic images of nanoparticles loaded with EGCG (A-i) and 
nanoparticles loaded with EGCG and MnO2 nanosheets (A-ii). Red arrows indicate the existence 
of MnO₂ nanosheets. Scale bar: 50 nm. (A-iii) A normal distribution of the sizes of the active 
anti-oxidizing nanoparticles. The diameter of at least fifty individual particles was measured 
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Figure 3.2 (cont.) manually based on the images in (A-ii). (B) Release profiles of EGCG over 24 
h at 37 °C. EGCG-loaded nanoparticles with and without MnO2 nanosheets were immersed in 
either phosphate buffered saline (PBS) (B-i) or PBS containing 200 µM H2O2 (B-ii). * represents 
the statistical significance of the difference of value for nanoparticles loaded with EGCG and 
MnO2 nanosheets in PBS containing 200 µM H2O2 and that for each of the three other conditions 
(*p < 0.05). (C) The rate of change of H2O2 concentration in media containing free MnO2 
nanosheets and nanoparticles with and without MnO2 nanosheets. (D) The increase in pressure of 
O2 gas (∆PO₂) at 24 h due to generation of O2 from the decomposition of H2O2. The values and 
error bars represent the average values and standard deviation of three individual samples per 
condition, respectively. * represents the statistical significance of the difference of values 













Figure 3.3. Analysis of PLGA and PLGA-b-HA nanoparticles tethered to MSCs. (A) Schematic 
showing the procedure to tether nanoparticles onto stem cells for 15 min at room temperature, 
followed by centrifugation to remove unbound particles. The nanoparticles were labeled by 
loading bovine serum albumin conjugated with Rhodamine B (red). (B) Representative confocal 
images of the cells tethered with the nanoparticles. Cell nuclei and cell membrane were stained 











Figure 3.4. Analysis of metabolic activity and morphology of MSCs in an oxidative 
environment. (A) Schematic demonstrating the procedure to assess the metabolic activity of stem 
cells encapsulated in collagen gel. The cells were subsequently exposed to 200 µM H2O2 for 2 h. 
The H2O2 solution was then replaced with fresh culture media either for measurement of 
metabolic activity or for further incubation for 1 or 4 days at 37 °C, 5% CO2. (B) Metabolic 
activity of stem cells of various conditions at different time points following exposure to 200 µM 
H2O2 for 2 h. The metabolic activity is expressed as the fraction of metabolically active cells with 
respect to the metabolic activity of untethered cells at 2 h without the H2O2 exposure. The values 
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Figure 3.4 (cont.) and error bars represent the average percentage of metabolic activity and 
standard deviation of three individual samples per condition, respectively. * represents the 
statistical significance in the difference of values between the indicated conditions (*p < 0.05). 
(C) Representative morphological images of stem cells of various conditions on Day 4 after the 2 
h H2O2 exposure. Image C-(i): untethered stem cells not exposed to H2O2. Images C-(ii) to C-(v) 
represent stem cells exposed to H2O2: untethered stem cells (C-ii), stem cells tethered with blank 
nanoparticles (C-iii), stem cells tethered with nanoparticles loading EGCG only (C-iv), and stem 















Figure 3.5. Secretion activity of MSCs. (A) Schematic describing the procedure to evaluate 
cellular secretion activity. Stem cells were encapsulated in collagen gel and incubated in media 
containing 200 µM H2O2 for 2 h. The media containing H2O2 was then replaced with fresh 
culture media and incubated for 1 and 4 days before collecting the conditioned media to measure 
the VEGF concentration. (B) VEGF concentration in the conditioned media of the various 
conditions as noted in the plot. The values and error bars represent the average concentration and 
standard deviation of three individual samples per condition, respectively. * represents the 




Figure 3.6. Analysis of the intracellular oxidative stress level and the antioxidant enzyme 
glutathione peroxidase (GPx) activity. (A) Representative fluorescence images of the CellROX® 
Green in the MSCs for analysis of the intracellular oxidative stress. Cells were cultured in media 
93 
 
Figure 3.6 (cont.) containing 200 µM H2O2 for 2 h and imaged immediately. Scale bar: 5 µm. 
(B) Mean gray value of CellROX® Green per cell was quantified using the ImageJ Software. 
The values were normalized with respect to that of stem cells without H2O2 exposure. These 
values and the error bars represent the average values and standard deviation from a minimum of 
five cells per condition, respectively. (C) Activity of GPx in stem cells following exposure to 
either culture media or media containing 200 µM H2O2 for 2 h. The value of GPx activity was 
normalized with respect to the number of metabolically active cells in each condition. The values 
and error bars represent the average values and standard deviation of three independent samples, 
respectively. * represents the statistical significance in the difference of values between the two 













Figure 3.7. In vivo chick chorioallantoic membrane (CAM) angiogenesis assay. (A) Schematic 
illustration of CAM assay. Eggshell was opened to expose CAM following 12 days of 
fertilization. MSCs encapsulated within collagen gels were incubated in media containing 200 
µM H2O2 for 2 h before implantation onto the CAM. The eggs were incubated for 6 days prior to 
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Figure 3.7 (cont.) harvesting the CAM. (B) Representative immunohistological images of the 
harvested CAM labeled with an antibody to α-smooth muscle actin (red arrows). Scale bar: 300 
µm. Images B-(i), B-(ii), B-(iii), and B-(iv) represent cross-sections of CAM implanted with the 
collagen gel containing no stem cells, the collagen gel encapsulating untethered stem cells, the 
collagen gel encapsulating stem cells tethered with nanoparticles containing EGCG only, and the 
collagen gel encapsulating stem cells tethered with nanoparticles loading EGCG and MnO2 
nanosheets, respectively. (C) Quantification of the total number of vasculature shown in the 
cross-sectional area of CAM where the sample was implanted on. (D) Quantification of the 
percentage of number of blood vessels in the respective range of cross-sectional area with respect 
to the total number of blood vessels in the CAM. The values and error bars represent the average 
values and standard deviation from two samples per condition, respectively. * represents the 
statistical significance in the difference of values between collagen gel encapsulating cells 
tethered with nanoparticles loading EGCG and MnO2 nanosheets and each of the three other 
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CHAPTER 4: ENHANCING THE RELEASE OF ANTICANCER DRUGS FROM 




This chapter features work that originally appeared in and has been reprinted with 
permission from: Teo, J. Y.; Chin, W.; Ke, X.; Gao, S.; Liu, S.; Cheng, W.; Hedrick, J. L.; Yang, 
Y. Y. pH and Redox Dual-Responsive Biodegradable Polymeric Micelles with High Drug 
Loading for Effective Anticancer Drug Delivery. Nanomedicine: Nanotechnology, Biology, 
Medicine. 2017, 13, 431-442. Copyright 2016 Elsevier Inc. I would like to acknowledge the 
contributions of W.C. for synthesizing PEG-SS-COOH and providing the synthesis scheme in 
Figure 4.2. X.K. and S.G. performed the animal studies, including tissue sectioning and 
histological analysis for Figure 4.8.  S.L., W.C., J.L.H., and Y.Y.Y. provided scientific input and 
assisted with the writing of the manuscript.  
 
4.2 Introduction  
Polymeric nanoparticles have been developed as carriers for the delivery of anticancer 
drugs to tumor sites via the enhanced permeability and retention (EPR) effect1,2. Amongst the 
various classes of polymeric materials, polycarbonates are well received for their excellent 
biocompatibility, enzymatic degradability in the body and non-toxicity of degraded products3. 
Unlike polyesters, functional groups can be easily incorporated onto polycarbonate backbone to 
improve stability, hydrophilicity, and drug loading capacity through non-covalent (e.g. hydrogen 
bonding and ionic interactions) and covalent interactions3-6. Particularly, nanoparticles fabricated 
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from diblock copolymers of polyethylene glycol (PEG) and polycarbonates are desired for the 
delivery of hydrophobic chemotherapeutic drugs such as doxorubicin (DOX). Driven mainly by 
hydrophobic interactions during self-assembly of amphiphilic copolymers, the hydrophilic PEG 
block minimizes exposure of the hydrophobic core to aqueous environment, and thus protects the 
drug molecules within the particles7.   
Despite a remarkable progress in nanoparticle-based drug delivery over the past decade, 
challenges to improve the therapeutic benefits of these drugs persist8. Issues of target specificity 
of therapeutic drugs as well as lethargic drug release at the tumor sites are the main attributes for 
the compromised efficacy of drug delivery systems9,10. A strategy to counter these problems is to 
develop stimuli-responsive nanoparticles sensitive to the tumor microenvironments or 
intracellular signals, which can facilitate release of encapsulated drugs at the target site. Of the 
various applied stimuli11-14, pH change and redox potential are the key stimuli to promote drug 
release in tumor tissues14. 
In normal extracellular matrix and blood, pH maintains at about 7.4, while the tumor 
microenvironment is acidic (pH 6.5) due to low oxygen supply in the intercellular 
environment14-16. The pH in endosomes and lysosomes is even lower at 5.0-6.0 and 4.5-5.0 
respectively17. By utilizing variations in pH value, many pH-responsive polymeric nanoparticles 
have been constructed to facilitate drug release at tumor tissues and/or in the 
endosomes/lysosomes10,18.  
Contrary to pH-sensitive nanoparticles, redox-responsive polymeric nanoparticles 
destabilize and release drugs in the cytoplasm10. GSH is a thiol-containing tripeptide produced in 
the cellular cytoplasm, and its concentration in intracellular compartments is in millimolar (~2-
10 mM), while that in the extracellular environment is in micromolar (~2-10 μM)10,18-21. 
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Moreover, the intracellular concentration of GSH in tumor cells is several folds greater than that 
in normal cells21. Thus, reduction-responsive linker such as disulfide bond would remain stable 
during blood circulation and in extracellular tissues but would be cleaved by GSH in the 
cytoplasm of cancer cells21. Such diversity in the redox potentials between the intracellular and 
extracellular compartments has been exploited to develop GSH-responsive polymeric 
nanoparticles14,10.  
 To this end, this study utilizes pH-responsive and GSH-sensitive moiety groups in the 
design of polycarbonate-based nanoparticles to enhance the release of DOX at tumor site and 
subsequently increases drug therapeutic efficacy.  We hypothesized that these particles would 
accelerate drug release in the endolyosomes and cytoplasm of cancer cells due to low pH and a 
high concentration of GSH, respectively (Figure 4.1). We examined this hypothesis by 
encapsulating DOX into nanoparticles comprising diblock copolymers of PEG and 
polycarbonate containing disulfide bonds and carboxylic acid groups on the same monomer unit, 
denoted as PEG-SS-COOH. 
In particular, we studied the effects of PEG/polycarbonate block length and feeding 
molar ratio of DOX to carboxylic acid group on the particle size, drug loading level, and drug 
release profile at different pH values with or without GSH. Furthermore, cytotoxicity of DOX-
loaded PEG-SS-COOH nanoparticles, together with free DOX and blank particles, was assessed 
against BT-474 human breast cancer cell line. We also evaluated cellular uptake and intracellular 
biodistribution of DOX-loaded nanoparticles under confocal microscopy. Finally, in vivo 
antitumor efficacy of DOX-loaded nanoparticles was investigated in a BT-474 human breast 





4.3.1 Synthesis of PEG and Polycarbonate Diblock Copolymers Containing Disulfide Bonds 
and Carboxylic Acid Groups (PEG-SS-COOH) 
By exploiting a well-established organocatalytic ROP route22, we synthesized a series of 
PEG-P(MTC-BnCl) diblock copolymers of varying monohydroxyl PEG lengths (5 and 10 kDa) 
and different degrees of polymerization (DP=7 and 15) with a functional cyclic carbonate 
monomer, MTC-BnCl (Figure 4.2-i). The copolymers were synthesized with a narrow molecular 
weight distribution (polydispersity: 1.2-1.3). The introduction of disulfide-functionalized 
carboxylic acid moieties along the polymeric chain was accomplished using methane 
thiosulfonates that are broadly utilized in the realm of biochemistry for site-specific protein 
modification of cysteine residues23,24. To this end, an excess of sodium methane thiosulfonate 
was reacted with the relevant precursor copolymer PEG-P(MTC-BnCl) to yield the polymeric 
methane thiosulfonate intermediate (PEG-P(MTC-MTS)) in near-quantitative conversion via 
nucleophilic substitution of the benzylic chloride group. Upon exposure to excess thiol (i.e. 3-
mercaptopropionic acid), the desired disulfide- and carboxylic acid-functionalized copolymers 
(PEG-SS-COOH) were obtained (Figure 4.2-ii). PEG-SS-COOH with molecular weight of PEG 
as 10 kDa and DP of 15 is denoted as polymer a. PEG-SS-COOH with molecular weight of PEG 
as 5 kDa and DP of 15 is denoted as polymer b. PEG-SS-COOH with molecular weight of PEG 
as 5 kDa and DP of 7 is denoted as polymer c.  
 
4.3.2 Preparation and Characterization of DOX-Loaded PEG-SS-COOH Nanoparticles 
We encapsulated DOX into the PEG-SS-COOH nanoparticles via the single 
emulsification method. Organic solvent containing the drug and copolymer was introduced into 
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water under sonication and the entire emulsion was dialyzed against water. The average particle 
size and polydispersity of the resulting DOX-loaded nanoparticles were measured with the 
dynamic light scattering unit. Particles prepared from polymer a (i.e. 10 kDa PEG, DP 15) at 1:1 
or 2:1 feeding molar ratio of DOX to COOH (R) had an average hydrodynamic diameter of 60 
nm and 51 nm, respectively, with a narrow size distribution (polydispersity: 0.14 and 0.10, 
respectively) (Table 2.1). The particles prepared at R=1 displayed a high drug loading level of 
24.1 wt%. By doubling the initial DOX loading level to R=2 the final drug loading level 
increased approximately two-fold to 47.2% while retaining similar average particle size. The 
encapsulation efficiency of DOX increased from 68.3% at R=1 to 90.6% at R=2.  
At the same feeding molar ratio of R=1, the average hydrodynamic diameter of 
nanoparticles prepared from polymer b (i.e. 5 kDa PEG, DP 15) was approximately 30 nm 
smaller than those fabricated from polymer a. In addition, these nanoparticles gave an excellent 
polydispersity index of 0.08, but at a higher DOX loading level (~40 wt%) and a greater 
encapsulation efficiency (~90%). (Table 2.1). When the hydrophobic block of the polymer was 
reduced to almost half (polymer c) from DP 15 to DP 7, drug loading level decreased drastically 
by about eight-fold. Upon re-dispersion in water, lyophilized DOX-loaded polymer b 
nanoparticles formed large aggregates. In contrast, lyophilized DOX-loaded polymer a 
nanoparticles (R=1 and R=2) were well dispersed in water, with average hydrodynamic diameter 
still within the ideal range of 10 to 100 nm. Accordingly, DOX-loaded polymer a nanoparticles 






4.3.3 Kinetic Stability of DOX-Loaded PEG-SS-COOH Nanoparticles 
We next examined the kinetic stability of DOX-loaded polymer a nanoparticles in the 
presence of sodium dodecyl sulfate, a destabilizing agent to the particles. The stability of 
particles was assessed based on the fluctuation of light intensity signal with respect to the 
intensity before adding the destabilizing agent, as determined by the dynamic light scattering 
unit. These particles showed excellent stability, with the relative intensity remained at 54% for 
R=1 and 68% for R=2 by 48 h (Figure 4.3). 
 
4.3.4 pH- and GSH-sensitive in vitro Release of DOX-Loaded PEG-SS-COOH 
Nanoparticles 
The in vitro release of DOX from DOX-loaded polymer a nanoparticles was investigated 
in a simulated physiological environment of pH 7.4 and endolysosomal pH of 5.0. A 
concentration of 10 mM GSH was used to mimic the cytoplasmic concentration of GSH. 
Generally, an expedited release of DOX was observed at pH 5.0, where ~30%-40% of DOX was 
released within the first 8 h for nanoparticles at both R=1 (Figure 4.4A) and R=2 (Figure 4.4B). 
On the contrary, within a period of 72 h at the physiological pH of 7.4, only ~10%-20% of DOX 
was released (Figures 4.4A and 4.4B). These results, thus, demonstrated pH-sensitive drug 
release. 
We also examined the effect of GSH on drug release. Addition of GSH at both pH 5.0 
and pH 7.4 considerably enhanced the rate of DOX release by ~1.3- to 2-fold, indicating that the 
particles were redox-responsive (Figures 4.4A and 4.4.B). Interestingly, the impact of acidic pH 
was more significant than the addition of GSH. Nevertheless, the highest release was clearly 
observed when the dual stimuli were applied concurrently. 
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4.3.5 Cellular Uptake and Intracellular Distribution of DOX 
The cellular uptake and intracellular distribution of free DOX and DOX-loaded polymer 
a nanoparticles (R=1 and R=2) in BT-474 human breast cancer cells was studied using confocal 
microscopy. To identify the intracellular distribution of DOX (red) delivered by the DOX-loaded 
particles, co-localization assays were performed with Hoechst 33258 (blue) and LysoTracker® 
Green (green) for nuclei and acidic compartments (endosomes and lysosomes) respectively. 
DOX signal was detected in the acidic organelles (yellow), the cytosols (red) and even in the 
nuclei (purple) of the cells treated with DOX-loaded particles after incubation of 2 h (Figure 
4.5A). This observation indicated that low pH and the presence of GSH might accelerate DOX 
release from the nanoparticles, which then entered the nuclei. At 6 h, a stronger signal of DOX 
was seen in the nuclei as a result of a higher amount of DOX released from the particles (Figure 
4.5B). 
 
4.3.6 In vitro Cytotoxicity of Free DOX and DOX-Loaded PEG-SS-COOH Nanoparticles  
We studied the extent of the cytotoxicity of the PEG-SS-COOH nanoparticles and free 
DOX to BT-474 human breast cancer cells by measuring their metabolic activity. According to 
the MTT assay which quantifies the fraction of metabolic active cells, blank polymer a 
nanoparticles induced negligible cytotoxicity against BT-474 cells, where more than 85% cells 
survived up to 1000 mg/L over 48 h (Figure 4.6A). On the contrary, DOX-loaded polymer a 
particles (R=1 and R=2) suppressed cell proliferation in a dose-dependent manner (Figure 4.6B), 
and induced a similar level of toxicity as free DOX. This demonstrated the effective release of 




4.3.7 In vivo Antitumor Efficacy of DOX-Loaded PEG-SS-COOH Nanoparticles 
In vivo antitumor efficacy of DOX-loaded polymer a nanoparticles was examined by tail-
vein injection in nude mice bearing BT-474 tumor (Figure 4.7A). DOX-loaded polymer a 
particles prepared at R=1 were the only formulation which resulted in a tumor volume shrinkage 
(relative tumor volume: ~57% at Day 17 post treatment) (Figure 4.7B). These DOX-loaded 
particles also exerted ~2.6-fold higher antitumor efficacy than DOX-loaded polymer a particles 
prepared at R=2. In contrast, blank nanoparticles did not show antitumor efficacy, suggesting 
that the antitumor activity of the DOX-loaded particles was attributed to the drug itself. More 
importantly, treatment with DOX-loaded nanoparticles (both R=1 and R=2) did not lead to 
considerable body weight loss over the entire treatment period, while free DOX caused 20% 
weight loss (Figure 4.7C). 
 
4.3.8 Histological Assay  
We further examined the in vivo antitumor efficacy and mechanism of DOX-loaded 
polymer a nanoparticles by analyzing TUNEL-stained histological sections of tumors and hearts. 
Brown DAB stain, which detects DNA fragmentation due to apoptosis, was used to identify 
apoptotic cells. The number of apoptotic cells in the tumors of mice treated with DOX-loaded 
polymer a nanoparticles at R=1 was ~2.4-fold higher than those which received saline and blank 
polymer a particles (Figures 4.8A and 4.8C). In parallel with its antitumor efficacy outcome, 
DOX-loaded polymer a nanoparticles prepared at R=1 induced a ~1.5-fold higher number of 
TUNEL-positive tumor cells than free DOX (Figures 4.8A and 4.8C).   
It is well known that cardiotoxicity is a major side effect of DOX treatment.25 Consistent 
with this fact, the number of apoptotic cells in the hearts of mice treated with free DOX was 4- to 
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6-fold higher than those from other groups Figures 4.8B and 4.8D). On the other hand, mice 
which received DOX-loaded polymer a nanoparticles prepared at R=1 and R=2 did not exhibit 




Ideal polymeric nanoparticles should possess the following traits: nano-sized; high drug 
loading capacity, stability in the blood without premature drug release, and biodegradability. In 
this study, we incorporated carboxylic acid and benzyl groups into biodegradable polycarbonates 
to increase the loading of amine-containing anticancer drug (DOX), to enhance stability via 
electrostatic interactions and π-π stacking, and to provide pH-sensitivity. Moreover, the GSH-
sensitive disulfide bonds were included in the design of nanoparticles to facilitate drug release 
inside the cytoplasm of cancer cells for improving the anticancer drug delivery. Synthesized via 
metal-free organocatalytic ring opening polymerization (ROP) method, PEG and carboxylic 
acid/disulfide bond-functionalized polycarbonate diblock copolymers, which had well-defined 
molecular length, allowed the study of structure-property relationship.   
These diblock copolymers successfully encapsulated DOX into particles via self-
assembly in water with hydrodynamic diameter of sub-nanometers (32-60 nm) in low 
polydispersity indices and of remarkable drug loading capacity (loading level: 24-47 wt%; 
encapsulation efficiency: 68-90%). In an aqueous environment of pH 7.0, ionic interactions 
between positively charged amino group of DOX (pKa 8.25)26,27 and negatively charged 
carboxylate group of the polymer (pKa 6.4)26 facilitated the high loading capacity of the 
nanoparticles. It was found that two-fold increment in the feeding molar ratio of DOX to 
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carboxylic acid group (R) doubled the drug loading level while maintaining the average particle 
size. This may be explained by the overall stronger hydrophobic interactions between DOX 
molecules themselves, as well as between DOX and the polymer. 
At the same feeding molar ratio of R=1, the particles formed from polymer b with a 
shorter PEG (5 kDa) had a smaller size as compared to particles formed from polymer a (10 kDa 
PEG). However, the DOX loading level increased dramatically by 1.6-fold. We attribute this 
increased drug loading capacity to the relatively higher hydrophobicity of polymer b, which 
might result in stronger hydrophobic interactions between DOX and the core of particles. On the 
other hand, shortening the hydrophobic block of the polymer from DP 15 to DP 7 (i.e. decreasing 
overall hydrophobicity of the polymer) caused an eight-fold reduction in the DOX loading level 
(polymer c). Taken together, we propose that the initial DOX loading, PEG length and overall 
hydrophobicity played a crucial role in affecting particle size and drug loading capacity. 
Kinetic stability is another important parameter of consideration when designing 
polymeric nanoparticles. This parameter predicts the behavior of the particles in the blood stream 
which is mainly depends on the interactions between the hydrophobic blocks of the polymer as 
well as between the core of particles and the drug molecules28. To enhance kinetic stability of 
particles, non-covalent interactions including stereocomplexation, hydrogen bonding and 
electrostatic interaction, as well as chemical cross-linking approaches have been employed29. 
Polymer a was synthesized from the functionalization of benzyl chloride-functionalized 
polycarbonate, which contained benzyl groups. In our previous work, DOX-loaded nanoparticles 
fabricated from PEG/carboxylic acid-functionalized polycarbonate diblock copolymers without 
benzyl groups were unstable26. They dissociated within minutes after being challenged by 
sodium dodecyl sulfate26. Therefore, we propose that the benzyl groups in polymer a may 
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enhance overall non-covalent interactions (van der Waals forces and π-π stacking) between the 
polycarbonate blocks themselves as well as between the core of particles and DOX. 
Consequently, DOX-loaded polymer a nanoparticles prepared at R=1 and R=2 displayed 
excellent kinetic stability in sodium dodecyl sulfate. 
Carboxylic acid groups and disulfide bonds were incorporated into the nanoparticles to 
render pH- and GSH-sensitivity, respectively. At the endolysosomal pH of 5.0, carboxylic acid 
groups in the polymer and primary amine group in DOX (pKa 8.25)26,27 were protonated. This 
weakened the ionic interactions between DOX and the polymer, and in turn, expedited the 
release of DOX. After 8 h, DOX release was too slow to be detected, where the remaining DOX 
molecules were possibly retained because of the strong hydrophobic interactions between DOX 
molecules themselves as well as between DOX and the nanoparticles. In the presence of GSH at 
the cytoplasmic concentration, disulfide bonds in the polymer were cleaved and thus, assisted 
DOX release. In contrast to pH, GSH had a milder effect in triggering drug release, and was 
prominent after 8 h. Since the disulfide bonds were strong30 and were positioned in the core of 
particles, we speculate that time was required for the penetration of GSH into the core and 
cleavage of these covalent bonds. Nonetheless, DOX release was the fastest when both stimuli 
were applied concurrently.   
In the viewpoint of intracellular trafficking, DOX-loaded particles would first be exposed 
to the acidic environment (~pH 5.0) in the endosomes following endocytosis. Exposure to 
protons would disrupt the ionic interactions between the amino group of DOX and carboxylic 
acid group of the polymer, facilitating initial release of DOX. Subsequent entry of the 
nanoparticles into cytoplasm would then further release DOX when GSH cleaves the disulfide 
bonds. As a result of the accelerated DOX release, DOX molecules encapsulated in the particles 
110 
 
were observed to accumulate in the nuclei at a comparable uptake efficiency as free DOX within 
2 h post incubation. Consequently, the DOX-loaded particles (both R=1 and R=2) inhibited 
proliferation of the BT-474 breast cancer cells at a similar drug concentration as free DOX. 
 Furthermore, the DOX-loaded polymer a nanoparticles as prepared at R=1 suppressed 
tumor growth more successfully and gave a higher number of apoptotic cells in the tumor tissue 
than that of free DOX.  We attribute this outcome to the efficacious delivery of DOX to the 
tumor tissue via the EPR effect, which was not as significant in the case of free DOX. Although 
the in vitro cytotoxicity of both DOX-loaded polymer a particles prepared at R=1 and R=2 was 
comparable, the nanoparticles prepared at R=2 did not perform as well as those prepared at R=1 
in vivo. Since the particles prepared at R=2 had a higher DOX content with a similar size and a 
comparable kinetic stability as those prepared at R=1, the number of administered particles at 
R=2 was reduced accordingly at the same given dose. As a result, we propose that fewer cancer 
cells endocytosed the DOX-loaded particles, leading to a poorer antitumor efficacy. More 
importantly, these nanoparticles mitigated the non-specific toxicity of DOX in mice and reduced 
the extent of cardiotoxicity due to the effective delivery of DOX.  
 Other pH- and GSH-sensitive nanoparticles have been developed which utilized disulfide 
bonds and acid-labile moieties such as ester14,31, hydrazone32,33 and acetal10 bonds to improve the 
intracellular release of DOX. Besides promoting drug release in acidic conditions, the carboxylic 
acid group in our nanoparticles could facilitate drug loading through ionic interactions with DOX 
molecules. In addition, the employment of benzyl groups in our design further improved the 
loading to as high as ~50%, a loading level which was not achieved by previous pH- and GSH-
dual responsive nanoparticles10,14,31-33. This, in turn, reduces the quantity of materials required 




Diblock copolymers of PEG and biodegradable polycarbonate functionalized with 
disulfide bonds and carboxylic acid groups were successfully synthesized and utilized to 
encapsulate DOX into nanoparticles. The resulting DOX-loaded nanoparticles exhibited small 
hydrodynamic diameter with narrow size distribution and high drug loading capacity. The drug 
loading capacity increased with increasing feeding molar ratio of DOX to carboxylic acid group. 
In addition, drug release from these nanoparticles was pH- and redox-responsive. At the 
endolysosomal pH and in the presence of GSH at the cytoplasmic concentration, drug release 
was dramatically accelerated. Furthermore, they exerted similar cytotoxicity to cancer cells as 
free DOX. Intravenous delivery of the DOX-loaded nanoparticles to tumor site of mouse 
xenograft model of breast cancer was efficacious with a reduction in the tumor volume as 
compared to that of free DOX. More importantly, unlike free DOX, the nanoparticles 
significantly reduced non-specific toxicity. Given their superior antitumor activity in vivo, these 
pH and redox dual-responsive biodegradable nanoparticles are promising carriers of anticancer 
drugs. 
 
4.6 Materials and Methods 
4.6.1 Materials 
All chemicals were obtained from Sigma-Aldrich (U.S.A.) and used as received unless 
specified. 1-(3,5-bis(Trifluoromethyl)-phenyl)-3-cyclohexyl-2-thiourea (TU) was prepared by 
polymerization of L-lactide (0.7 M, deuterochloroform) in the presence of 10% N,N-
dimethylcyclohexylamine with 10% thiourea and 1% 4-pyrene-1-butanol at 25 °C for 72 h34. TU 
was then dissolved in tetrahydrofuran (THF), stirred with CaH2, filtered to get rid of moisture, 
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and vacuum dried to remove the residual solvent. 1,8-Diazabicyclo [5,4,0]undec-7-ene (DBU) 
was stirred over CaH2, vacuum distilled, and then transferred to a glove box. MTC-BnCl 
monomer was synthesized by reacting oxalyl chloride (2.45 mL, 28.5 mmol) with MTC-OH 
(3.08 g, 19.3 mmol) in THF for 1 h under inert atmosphere. The resulting off-white solid product 
was further reacted with a mixture of p-chloromethyl benzyl alcohol (2.79 g 17.8 mmol) and 
pyridine (1.55 mL, 19.3 mmol) in dichloromethane for overnight.22 Doxorubicin-hydrochloride 
(DOX) was bought from Merck (Singapore). 3-[4,5-Dimenthylthiazol-2-yl]-2,5-diphenyl 
tetrazolium bromide (MTT) solution was prepared by dissolving MTT in phosphate-buffered 
saline (PBS, pH 7.4) at 5 mg/mL, which was then filtered to remove blue formazan crystals 
using a 0.22 μm filter.  
 
4.6.2 Cell Culture  
BT-474 human breast cancer cell line was purchased from ATCC (U.S.A). Cells were 
cultured in RPMI-1640 medium containing 25 mM Hepes and L-Glutamine (Lonza, Singapore) 
supplemented with 10% fetal bovine serum (FBS, Life Technologies, Singapore.), 100 U/ml 
penicillin (Lonza, Singapore) and 100 µg/ml streptomycin (Lonza, Singapore) under 37 °C, 5% 
CO2.  
  
4.6.3 Synthesis of PEG-SS-COOH  
a) Synthesis of PEG and Poly(MTC-BnCl) Diblock Copolymers 
Diblock copolymers of PEG and poly(MTC-BnCl) were synthesized by metal-free 
organocatalytic ROP of MTC-BnCl monomer with PEG (MW 10 kDa) as macroinitiator. In a 
glove box, MTC-BnCl (299 mg, 1.0 mmol) was charged to a reaction vial containing 2 mL of 
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TU-containing anhydrous dichloromethane (DCM) (18.5 mg, 0.05 mmol). PEG (500 mg, 0.05 
mmol) was added to the reaction before adding DBU (7.46 μL, 0.05 mmol). The polymerization 
proceeded for one hour at room temperature under stirring. Upon reaction completion as 
ascertained from gel permeation chromatography (GPC) chromatography (Waters 2690, MA, 
U.S.A.), the catalyst was quenched using an excess of benzoic acid (10 mg, 0.08 mmol). The 
crude product was then precipitated twice into cold diethyl ether, centrifuged, harvested and 
vacuum dried to yield a white powdery solid (PEG-P(MTC-BnCl), 89% yield). 1H NMR (400 
MHz, CDCl3, 22 °C): δ 7.39 – 7.27 (m, Ph-H, overlapped with CDCl3 peak), 5.18 – 5.08 (m, 
30H, -OCOCH2-), 4.55 (m, 29H, -CH2Cl), 4.35 – 4.19 (m, 58H, -OCOOCH2- and -OCH2CCH3-
), 3.71 – 3.59 (bs, 909H, PEG -CH2-), 1.29 – 1.18 (m, 45H, -CH3). 
b) Functionalization of PEG-P(MTC-BnCl) Diblock Copolymers with Thiosulfonate  
The aforementioned diblock copolymer PEG-P(MTC-BnCl) (0.60 g, 0.04 mmol) was 
initially dissolved in a 5:1 acetonitrile:methanol mixture (6 mL), and added to a reaction vial. 
Sodium methanethiosulfonate (NaMTS) was subsequently added in excess (2 equiv. of benzyl 
chloride groups). The reaction proceeded overnight under stirring at 50˚C. The solvent was then 
removed in vacuo. The crude mixture was re-dissolved in DCM, and NaCl as well as unreacted 
NaMTS were removed by filtration. Precipitation in cold diethyl ether afforded the copolymer 
PEG-P(MTC-MTS) (90% yield) as a waxy white solid. 1H NMR (400 MHz, d6-DMSO, 22 °C): 
δ 7.46 – 7.27 (m, 59H, Ph-H), 5.11 (m, 30H, OCOCH2-), 4.51 – 4.43 (m, 29H, -CH2S-), 4.33 – 
4.12 (m, 61H, -OCOOCH2- and -OCH2CCH3-), 3.51 (bs, 909H, PEG -CH2-), 3.35 – 3.31 (m, 
46H, -SO2CH3), 1.21 – 1.07 (m, 45H, -CH3). 
c) Synthesis of PEG and Polycarbonate Diblock Copolymers Containing Disulfide Bonds and 
Carboxylic Acid Groups (PEG-SS-COOH)  
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For the subsequent functionalization to the disulfide copolymer, PEG-P(MTC-MTS) 
(0.50 g, 0.03 mmol) that was dissolved in anhydrous THF (5 mL) was added to a reaction vial. 3-
Mercaptopropionic acid was then added in excess (15 equiv. of benzyl chloride groups), and the 
reaction was allowed to proceed overnight under stirring at 40˚C. Upon reaction completion, the 
reaction mixture was precipitated twice in cold diethyl ether, centrifuged, harvested and vacuum 
dried to afford the crude copolymer PEG-SS-COOH as a waxy white solid. Further purification 
was carried out via dialysis against DMSO for 48 h. After removal of the solvent by precipitation 
in diethyl ether twice, the resultant polymer was re-dissolved in de-ionized (DI) water and 
lyophilized to yield a white flaky solid (79% yield). 1H NMR (400 MHz, d6-DMSO, 22 °C) δ 
7.36 – 7.17 (m, 60H, Ph-H), 5.07 (m, 2H, OCOCH2-), 4.32 – 4.09 (m, 59H, -OCOOCH2- and -
OCH2CCH3-), 3.97 – 3.86 (m, 28H, -CH2S-), 3.50 (bs, 909H, PEG -CH2-), 2.75 – 2.64 (m, 28H, 
-SCH2CH2COOH), 2.56 – 2.49 (m, overlapped with d6-DMSO peak, -SCH2CH2COOH), 1.20 – 
1.04 (m, 45H, -CH3). 
 
4.6.4 Preparation and Characterization of DOX-Loaded PEG-SS-COOH Nanoparticles  
DOX-loaded nanoparticles of various feeding molar ratios, R=[DOX]/[COOH], were 
fabricated using a sonication/membrane dialysis method as described previously.26 Briefly, DOX 
was dissolved in 1.5 mL of N,N-dimethylacetamide (DMAc) and neutralized with 
trimethylamine in three moles excess. Polymer was dissolved in 0.5 mL of DMAc and mixed 
with the DOX solution by vortexing. The resulting solution was then added dropwise into 10 mL 
of DI water while under sonication for 2 min using a probe-based sonicator of 130 W (Vibra Cell 
VCX 130, U.S.A.). Excess DOX and solvents were subsequently removed through dialysis 
against 1000 mL of DI water using a dialysis bag with molecular weight cut-off (MWCO) of 
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1000 Da (Spectra/Por 7, Spectrum Laboratories Inc.), and the water was changed at 2 h, 5 h and 
24 h from start of dialysis. DOX-loaded nanoparticle solution inside the dialysis bag was 
collected at 48 h and used for further studies or lyophilized for 2 days. Each experiment was 
performed in triplicates.  
Size of freshly prepared nanoparticle solution was measured using a particle sizer 
(Malvern (ZEN 3600) Zetasizer Nano ZS, UK). To determine the DOX content, 100 μL of 
nanoparticle solution was diluted in 900 μL of dimethyl sulfoxide (DMSO), or 1 mg of 
lyophilized DOX-loaded nanoparticles was dissolved in 1 mL of DMSO, and the absorbance of 
DOX measured using a UV-Vis spectrophotometer (UV 2501 PC Shimadzu, Japan) at 480 nm. 
A standard curve was constructed to evaluate DOX concentration in the range of 1 to 1000 mg/L. 
DOX loading was obtained using the following formula:  
 
Encapsulation efficiency of DOX was determined as follows:  
 
 
4.6.5 Analysis of Kinetic Stability of DOX-Loaded PEG-SS-COOH Nanoparticles 
The kinetic stability of freshly prepared DOX-loaded nanoparticles was evaluated 
phosphate buffered saline (PBS) containing sodium dodecyl sulfate (SDS, 2.23 mg/mL) as a 
destabilizing agent at room temperature. The change in relative scattered light intensity was 
monitored as a function of time using the dynamic light scattering unit (Malvern (ZEN 3600) 
Zetasizer Nano ZS, UK). 
116 
 
4.6.6 Analysis of pH- and GSH-Sensitive in vitro Release of DOX from PEG-SS-COOH 
Nanoparticles 
To quantitatively assess the release rate of DOX, lyophilized DOX-loaded nanoparticles 
(1 mg/mL) were dissolved in PBS buffer (150 mM, pH 7.4) with or without GSH (10 mM), and 
acetate buffer (150 mM, pH 5.0) with or without GSH (10 mM), and transferred into dialysis 
bags with MWCO of 1000 Da (Spectra/Por 7, Spectrum Laboratories Inc.). The bags were then 
immersed into the same buffered solutions (20 mL each) and subjected to shaking at 100 rpm at 
37 ⁰C (Polyscience, Spectra-Teknik (S) Pte Ltd., Singapore). Periodically, 1 mL of release 
medium was collected and replaced with 1 mL of fresh buffer to keep the volume of release 
medium constant. The absorbance of DOX was measured using the UV-Vis spectrophotometer 
(UV 2501 PC Shimadzu, Japan) at 480 nm. DOX content was then calculated using the standard 
curve of DOX in the respective buffers. 
 
4.6.7 Analysis of Cellular Uptake and Intracellular Distribution of DOX-Loaded PEG-SS-
COOH Nanoparticles  
The cellular uptake and intracellular distribution of DOX-loaded nanoparticles in BT-474 
human breast cancer cells were investigated using confocal microscopy. The cells were seeded at 
a density of 1×105 cells/well onto a 4 well-cover slip borosilicate glass chamber (NUNC) at 37 
°C, 5% CO2. After 24 h, the medium was replaced with cell culture medium containing free 
DOX or freshly prepared DOX-loaded nanoparticles (10 µM equivalent DOX concentration) and 
the cells were incubated for another 2 h or 6 h at 37 °C, 5% CO2. The medium was removed, and 
the cells were washed three times with cold PBS, followed by staining with Hoechst 33258 (5 
μg/mL) and LysoTracker® Green (Life Technology, 75 nM) for 30 min at 37 °C, 5% CO2. The 
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cells were then washed three times with PBS and observed using a confocal laser scanning 
microscope (CLSM, Carl Zeiss LSM 510 META inverted confocal microscope, Germany). 
Hoechst dye was excited at 350 nm with emission at 480 nm while LysoTracker® Green was 
excited at 488 nm with emission at 532 nm. DOX was excited at 532 nm with emission at 595 
nm. All observations were conducted under the same conditions. 
 
4.6.8 Analysis of in vitro Cytotoxicity of DOX-Loaded PEG-SS-COOH Nanoparticles  
The cytotoxicity of DOX-loaded nanoparticles against BT-474 human breast cancer cells 
was determined by measuring the cellular metabolic activity through MTT assay. BT-474 cells 
were seeded onto 96-well plates at a density of 5 × 10³ cells per well and incubated overnight in 
100 μL of medium at 37 °C, 5% CO2. Free DOX, freshly prepared DOX-loaded nanoparticles 
and nanoparticles without DOX were dissolved in medium at various concentrations. The sample 
solution (100 μL) was used to replace the medium in each well and the plates were incubated at 
37 °C, 5% CO2 for 48 h. Six replicates were tested for each concentration and only medium was 
added for control. At the end of the treatment, each sample solution was substituted with 100 μL 
of fresh medium and 20 μL of MTT solution (5 mg/mL in PBS). The plates were then 
maintained at 37 °C, 5% CO2 for 4 h. Subsequently, the medium solution was removed and 150 
μL of DMSO was added to each well to dissolve the purple formazan crystals internalized by 
live cells. After a gentle agitation for 15 min, the absorbance of formazan crystals was taken to 
be that at 550 nm subtracted by that at 690 nm using a microplate reader (TECAN, Switzerland). 





4.6.9 Analysis of in vivo Antitumor Activity 
Female BALB/c nude mice at 6 weeks of age (body weight: 20-22 g) were provided by 
the Singapore Biological Research Center (BRC). BT-474 cells (density of 1 × 107 per mouse) 
were suspended in 200 µL of a mixture solution of Matrigel and PBS (volume ratio: 50/50) and 
subcutaneously injected into the right flank of the mouse. Estradiol pellet (0.72 mg/pellet, 60 
days release) was subcutaneously administered into each mouse one day before the inoculation. 
When the tumor volume reached approximately 200 mm3 on the 14th day (recorded as day 0), the 
mice were randomly divided into 5 groups (7 or 8 mice per group): Group 1 for 0.9 % saline as 
control, Group 2 for blank nanoparticles, Group 3 for free DOX, Group 4 for DOX-loaded 
nanoparticles (R=1), and Group 5 for DOX-loaded nanoparticles (R=2). The dose of DOX in all 
formulations was 5 mg/kg. Freshly prepared formulations were given to the mice via tail vein 
injection on day 0, 3, 6 and 10. At predetermined time points, mice were weighted, and tumor 




4.6.10 Analysis of Histological Assay 
At the end of the in vivo antitumor activity study, the mice were sacrificed, and the 
tumors and hearts were harvested for terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labeling (TUNEL) assay. The samples were embedded in paraffin and stained using 
standard techniques after fixation using 10 % formalin solution. To visualize nuclei, hematoxylin 
was used to counterstain the slides. The number of apoptotic cells in each sample was obtained 
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by averaging the number of TUNEL-positive nuclei in 5 representative fields of 20X 
magnification under a light microscope (Leica DMI6000 B, Germany). 
 
4.6.11 Statistical Analysis 
All data are presented as mean  standard deviation. Significance among two 




















4.7 Figures and Table 
 
 
Figure 4.1. Enhanced intracellular release of DOX from pH-and glutathione (GSH)-responsive 
nanoparticles. The nanoparticles contain carboxylic acid groups and disulfide bonds which 
would be disrupted in the acidic environment of endolysosomes and GSH-rich cytoplasm of 





Figure 4.2. Chemical synthesis scheme of PEG-SS-COOH. (i) Synthesis of PEG-P(MTC-BnCl) 
diblock copolymers via organocatalytic ring opening polymerization. (ii) Post-polymerization 
functionalization of pendant benzyl chloride to disulfide-containing carboxylic acid moieties via 
a reactive methane thiosulfonate intermediate polymer to yield PEG-SS-COOH. PEG-SS-COOH 
with molecular weight of PEG as 10 kDa and degree of polymerization of 15 is denoted as 




Figure 4.3. Kinetic stability of DOX-loaded polymer a nanoparticles (R=1 and R=2) in the 
presence of sodium dodecyl sulfate (SDS) over 48 h. The stability of particles was assessed 
based on the fluctuation of light intensity signal with respect to the intensity before adding SDS, 
as determined by dynamic light scattering. The values and error bars represent the average and 
standard deviation of three individual samples, respectively. * represents the statistical 
significance of difference in the values between DOX-loaded polymer a nanoparticles at R=1 





Figure 4.4. Time dependent cumulative release of DOX from DOX-loaded polymer a 
nanoparticles prepared at (A) R=1 and (B) R=2 at different pH values with or without the 
presence of GSH at 37 °C. The values and error bars represent the average and standard 
deviation of three individual samples, respectively. * represents the statistical significance of 





Figure 4.5. Confocal images of BT-474 human breast cancer cells after incubation with free 
DOX and DOX-loaded polymer a nanoparticles (R=1 and R=2) for (A) 2 h and (B) 6 h at 37 °C, 
5% CO2. Cell nuclei and acidic organelles (endosomes and lysosomes) were stained with 
Hoechst dye (blue) and LysoTracker® Green (green), respectively. Concentration of DOX was 





Figure 4.6. Metabolic activity of BT-474 cells after 48 h of incubation with (A) blank polymer a 
nanoparticles, (B) free DOX and DOX-loaded polymer a nanoparticles at 37 °C, 5% CO2. The 
metabolic activity of cells was expressed as the percentage of the fraction of metabolically active 
cells with respect to that of untreated cells as determined by MTT assay. The values and error 






Figure 4.7. In vivo antitumor efficacy of PEG-SS-COOH nanoparticles loaded with DOX in 
cancer xenograft mouse model. (A) Illustration depicting the procedure of tumor inoculation of 
BT-474 human breast cancer cells and tail-vein injection of formulations: 0.9% saline, blank 
polymer a nanoparticles, free DOX (5 mg/kg), DOX-loaded polymer a nanoparticles. An 
equivalent concentration of DOX at 5 mg/kg was used for all conditions. 7-8 mice were used per 
condition. The dimensions of tumor were measured with a Vernier caliper at the designated 
timepoints and used to calculate the volume of tumor. (B) Relative tumor volume was expressed 
as a percentage of the tumor volume with respect to the volume on Day 0. a represents the 
statistical significance of difference in the values between DOX-loaded polymer a nanoparticles 
R=1 and each other condition (p < 0.05). (C) The body weight of mouse. b represents the 
statistical significance of difference in the values between free DOX and each other condition (p 
< 0.05). The values and error bars in (B) and (C) represent the average values and standard 




Figure 4.8. Histological analysis of BT-474 xenograft tumor and heart tissues at Day 17 post 
administration of various formulations for TUNEL-positive apoptotic bodies (organs/tissues 
obtained from a representative mouse in each treatment group). (A) Tumor sections and (B) heart 
sections from mice treated with 0.9% saline, blank polymer a nanoparticles, free DOX (5 
mg/kg), DOX-loaded polymer a nanoparticles (DOX equivalent: 5 mg/kg). Scale bar: 100 µm. 
Quantitative analysis of mean apoptotic bodies per field in (C) tumor and (D) heart sections. The 
values and error bars represent the average values and standard deviation of 5 representative 









Table 4.1. Properties of DOX-Loaded PEG-SS-COOH nanoparticles (mean ± standard 
deviation, n=3) 
 
MW=Molecular weight; DP=Degree of polymerization; R=feeding molar ratio of DOX to 


























level (wt %) 
EE (%) 
a 10 15 1 60 ± 9 0.14 ± 0.01 24.1 ± 1.6 68.3 ± 4.5 
a 10 15 2 51 ± 3 0.10 ± 0.01 47.2 ± 1.5 90.6 ± 2.8 
b 5 15 1 32 ± 1 0.08 ± 0.02 39.7 ± 0.5 89.7 ± 2.8 
c 5 7 1 32 ± 1 0.25 ± 0.07 5.2 ± 0.7 15.1 ± 2.0 
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CHAPTER 5: CONCLUSIONS  
 
5.1 Summary   
Successful delivery of therapeutics via the intravenous route entails the ability of 
therapeutics to overcome several barriers as they make their way to the intended destination. 
This dissertation presents design strategies involving polymeric nanoparticles which aim to 
improve the delivery of mesenchymal stem cells (MSCs) and doxorubicin (DOX) to acute 
ischemic tissues and cancer cells, respectively.  
 We sought to enhance the transendothelial migration and transport of MSCs to the site of 
ischemia in Chapter 2. In situ activation of cellular expression of CXC chemokine 4 (CXCR4) 
was achieved by tethering the surface of stem cells with nanoparticles that sustainably released 
stromal cell-derived factor-1α (SDF1α), a model chemokine to sensitize the CXCR4. These 
nanoparticles were fabricated from block copolymers of poly(D,L-lactide-co-glycolide) and 
hyaluronic acid (PLGA-b-HA); PLGA was employed as the carrier of the chemokine, while HA 
was utilized to facilitate binding through HA-CD44 interactions with the stem cells. Such 
proximal delivery of SDF1α to the stem cells increased the population of CXCR4-expressing 
MSCs. Consequently, these stem cells exhibited a higher transendothelial migration in vitro and 
a greater trafficking to the ischemic hindlimb of a mouse following intravenous administration. 
In Chapter 3, we aimed to improve the survival of extravasated stem cells in the oxidative 
tissues. Adopting the same surface tethering approach, EGCG was encapsulated into PLGA-b-
HA nanoparticles and bound onto the MSCs. Rescuing stem cells from H2O2-induced death 
would demand fast release of the antioxidants in response to the level of reactive oxygen species. 
To achieve this, we leveraged the catalytic property of MnO2 nanosheets to decompose H2O2 into 
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water and O2 gas. By encapsulating EGCG together with MnO2 nanosheets, the release of EGCG 
was accelerated in the presence of H2O2 due to the thrust force generated from the rise in O2 
partial pressure in the particles. EGCG consequently improved the activity of glutathione 
peroxidase in H2O2-treated MSCs. Both the depletion of H2O2 by MnO2 nanosheets and the 
higher intracellular antioxidant capacity contributed to the increased metabolic activity and 
secretion activity of MSCs in sub-lethal concentrations of H2O2. These stem cells, in turn, 
performed a greater angiogenic potential in vivo.  
In Chapter 4, we presented stimuli-responsive nanoparticles to tackle the challenge of 
lethargic release of entrapped DOX in cancer cells. Diblock copolymers of PEG and 
polycarbonate containing carboxylic acid groups and disulfide bonds (PEG-SS-COOH) were 
employed to render pH and GSH sensitivity, respectively. At the endolysosomal pH and in the 
presence of GSH at the cytoplasmic concentration, drug release was dramatically accelerated, 
and DOX was detected in the nuclei of human breast cancer cells within a short period of time. 
Besides improving the antitumor efficacy in a mouse xenograft model of breast cancer, these 
nanoparticles helped mitigate the non-specific toxicity of DOX.  
Taken together, these design strategies to overcome the biological barriers to cell and 
drug delivery have allowed for a higher accumulation of therapeutics in the diseased tissues with 
the given doses and will contribute to enhancing the therapeutic efficacy of numerous vascular-







5.2 Future Directions 
The polymeric nanoparticles used for the intravenous transportation of MSCs and DOX 
could be easily modified to further improve their accumulation at the target sites.  
The PLGA-b-HA nanoparticles can be extended to enhancing the adhesion of circulating 
MSCs to endothelium, the preceding stage to transendothelial migration. Since the inflamed 
endothelium often overexpresses vascular cell adhesion molecules (VCAM), the nanoparticles 
can be covalently conjugated with VCAM-binding peptides, for example, to facilitate the 
interaction of stem cells with the endothelium. To promote the transendothelial migration and 
cellular survival, MSCs could be tethered with these nanoparticles containing recombinant 
SDF1α and EGCG before injecting them into the bloodstream. The therapeutic efficacy of stem 
cells which have extravasated and survived in the oxidative tissues needs to be further evaluated. 
The perfusion of blood flow at the ischemic site and tissue functionality are good measurement 
parameters.  
The PEG-SS-COOH nanoparticles used herein utilized passive delivery via the enhanced 
permeability and retention effect. To achieve a targeted delivery of doxorubicin, the 
nanoparticles can be tagged with an array of tumor-targeting ligands such as antibody, peptide, 
folic acid etc. This would increase the local drug concentration at the tumor site while sparing 
non-cancerous cells from the toxicity of the drug. In addition, the release of DOX could be 
further improved by repositioning the stimuli responsive moieties. For example, the disulfide 
bonds can be incorporated in between the blocks of PEG and polycarbonate. Bond cleavage 
between the two blocks results in a total disintegration of the particles, and thus sets free more 
drug molecules.  
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Overall, the nanoparticles developed in this dissertation served as a carrier of therapeutics 
and could be structurally modified according to the disease of interests for the maximum 
therapeutic outcome.  
 
 
 
 
 
